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Abstract 
Psychotic disorders are severe and potentially disabling mental disorders which rank among 
the world's top 10 causes of chronic disability and produce high healthcare costs. First-line 
treatment with antipsychotic medication is associated with only medium effect sizes for 
positive symptoms and several limitations. Research has thus increasingly embraced new and 
complementary treatment approaches, namely the early detection and intervention research 
and the development of psychological interventions. This thesis aimed to address unresolved 
research questions in these areas. Article 1 and 2 focused on the early detection and 
intervention of psychotic disorders and investigated predictors of study drop-out, service 
disengagement, and long-term clinical and functional outcome in patients at clinical high risk 
for psychosis (CHR-P). Article 3 analyzed moderators of individualized Metacognitive 
Training (MCT+), a theory-driven intervention designed to improve delusional symptom 
severity. In Article 1, 36% of CHR-P patients dropped out and/or disengaged within 5 years. 
A late study inclusion period, associated with more frequent follow-ups and higher 
participation burden, was predictive for higher risk of drop-out and disengagement. In Article 
2, remission from CHR-P status after 10 years was estimated as 51%. Better baseline 
psychosocial functioning was associated with a higher rate of remission. However, only a 
minority of patients fully recovered clinically and functionally. In Article 3, the occurrence of 
the jumping-to-conclusions bias and low self-esteem were associated with larger 
improvements over time in MCT+ compared to an active control intervention. Article 1 and 2 
underline the importance of individually tailored treatment planning and call for the right 
balance between too high-frequency assessments on one hand, and a lack of treatment care for 
patients experiencing long-term clinical symptoms and functional impairments on the other. 
The findings of Article 3 provide useful criteria for selecting patients who might particularly 
benefit from MCT+.  
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Introduction 
Psychotic disorders such as schizophrenia are severe mental disorders which 
encompass positive symptoms such as hallucinations, delusions or disorganized speech, and 
negative symptoms such as alogia, anhedonia, and avolition (American Psychiatric 
Association, 2013). Recent findings from epidemiological studies suggest that the median 
lifetime prevalence of schizophrenia in the general population is approximately 0.3-0.7% 
(American Psychiatric Association, 2013; McGrath, Saha, Chant, & Welham, 2008). 
Schizophrenia typically emerges in adolescence or early adulthood (Häfner, Riecher-Rössler, 
Maurer, Fätkenheuer, & Löffler, 1992), a time in life characterized by important psychosocial 
developments (McGorry & Goldstone, 2016). It has been reported that schizophrenia 
occupies the eighth-largest share of disability-adjusted life years in European adults 
(Klosterkötter, 2016; Wittchen et al., 2011). Additionally, the disorder has been associated 
with high premature mortality rates leading to about 15 years of potential life lost and 
increased rates of multiple somatic disorders (Hjorthøj, Stürup, McGrath, & Nordentoft, 
2017; Laursen, 2019). Numerous studies have reported that schizophrenia and other psychotic 
disorders are associated with impairments in social, occupational, vocational, and cognitive 
functioning (Gold, 2004; Harvey & Strassnig, 2012; Velthorst et al., 2017). Further, the 
burden of psychotic disorders caused by stigma and discrimination is amongst the highest of 
mental disorders (Rössler, Salize, van Os, & Riecher-Rössler, 2005; Schultze-Lutter et al., 
2015). Psychotic disorders share high lifetime comorbidity rates with other mental disorders 
such as substance use disorders, anxiety disorders, and affective disorders (Buckley, Miller, 
Lehrer, & Castle, 2009; Siu, Chong, & Lo, 2018; Tsai & Rosenheck, 2013). Importantly, the 
period over which a psychosis remains untreated is associated with more severe 
psychopathology, delayed and incomplete symptom remission, as well as greater relapse risk 
(Boonstra et al., 2012; Hill et al., 2012; Oliver et al., 2018; Penttilä, Jääskeläinen, Hirvonen, 
Isohanni, & Miettunen, 2014). 
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According to the Clinical Practice Guidelines and the guidelines of the National 
Institute for Health and Care Excellence (NICE), psychotic disorders are treated with 
antipsychotic medication, often considered as the first-line treatment (American Psychiatric 
Association, 2019; National Institute for Health and Care Excellence, 2014). 
Pharmacotherapy with antipsychotic medication has been shown to reduce both positive 
symptoms of psychotic disorders as well as the risk of relapse (Haddad & Correll, 2018). 
However, treatment with antipsychotic medication has been associated with several 
limitations such as only medium effect sizes on positive symptoms (Haddad & Correll, 2018; 
Leucht et al., 2017), considerable side effects, and high treatment nonadherence (Garcia et al., 
2016; Lally & MacCabe, 2015; Leucht et al., 2017). 
The growing realization of these limitations has led to increased efforts to develop 
new approaches for the treatment of psychotic disorders. One of these promising approaches 
represents the early detection and intervention of psychotic disorders, which has been a highly 
productive research area over the last two decades. A second approach is the development of 
complementary psychological interventions for the treatment of positive symptoms, which 
resulted in the development of a theory-driven intervention, namely the individualized 
Metacognitive Training for psychosis (MCT+). This thesis aimed to investigate social 
psychiatric and treatment related outcomes in the psychosis spectrum within the context of 
these two approaches.  
Theoretical Background 
Early Detection and Intervention in Psychosis 
During the past 20 years, various international clinical and research programs focusing 
on the early detection and intervention of psychosis have been established (McGorry, 
Edwards, Mihalopoulos, Harrigan, & Jackson, 1996; Miller et al., 1999; Riecher-Rössler et 
al., 2007; Yung et al., 1996). Most first episodes of psychotic disorders (FEP) are preceded by 
an extended period of functional impairment and nonspecific symptoms. Typically, these are 
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followed by subthreshold psychotic symptoms, which emerge prior to the development of 
frank psychosis. On average, this period lasts around 2-5 years and can retrospectively be 
referred to as the prodrome of the disorder (Häfner et al., 1998; Riecher-Rössler et al., 2006). 
Help-seeking patients who are at risk of developing a psychotic disorder are referred to as 
clinical high risk for psychosis (CHR-P) or at-risk mental state (ARMS) patients. In line with 
the suggestion of Fusar-Poli (2017), the term CHR-P will be used throughout this thesis. 
CHR-P patients can be identified using a set of operationalized criteria known as the ultra-
high risk (UHR) criteria, which require the presence of one or more of the following criteria: 
Attenuated psychotic symptoms (APS), brief limited intermittent psychotic symptoms 
(BLIPS), genetic risk and deterioration syndrome (GRD) or unspecified prodromal symptoms 
(UPS). Furthermore, the Basic Symptom (BS) criteria can as well be used for identification of 
CHR-P patients (Fusar-Poli et al., 2013). BS are subtle, subclinical and self-experienced 
disturbances in stress tolerance, affect, thinking, speech, perception or drive (Schultze-Lutter, 
Addington, Ruhrmann, & Klosterkötter, 2007). As BS criteria were not used in this thesis, 
they will not be further elaborated here. A full model of psychosis onset suggested by Fusar-
Poli et al. (2013) according to the UHR criteria, as well as further explanations of the criteria, 
can be found in Appendix A.  
To determine whether patients meet the above mentioned UHR criteria, different 
instruments have been developed, such as the Basel Screening Instrument for Psychosis 
(BSIP; Peralta et al., 2019; Riecher-Rössler et al., 2008), the Comprehensive Assessment of 
At-Risk Mental States (CAARMS; Yung et al., 2005), and the Structured Interview for 
Prodromal Symptoms (SIPS; Miller et al., 2003). Definitions of the UHR criteria slightly 
differ depending on the instrument used. Detailed UHR and FEP criteria according to the 
BSIP (Riecher-Rössler et al., 2008), which was used in this thesis can be found in Appendix 
B. Numerous studies have investigated the predictive accuracy of the UHR criteria. A meta-
analysis reported a cumulative mean risk for transition to psychosis of 10% after 6 months, 
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17% after 1 year, 20% after 2 years and 25% after 3 years (Fusar-Poli et al., 2016). Thus, 
independently from the psychometric instrument used, less than one third of patients 
identified as being at-risk for psychosis develop frank psychosis during follow-up. The 
currently used interviews have been shown to have a high sensitivity (meta-analytical finding 
= 0.96) but a rather low specificity (meta-analytical finding = 0.47) when used in clinical 
samples of help-seeking patients (Fusar-Poli et al., 2015). 
There is a clear rationale for the early detection and intervention in psychosis. It has 
been shown that interventions in CHR-P patients are associated with symptom reduction, 
improvement of social and vocational outcomes and a reduction of the risk of transition to 
frank psychosis (McGorry, Hartmann, Spooner, & Nelson, 2018; Schmidt et al., 2015; 
Schultze-Lutter et al., 2015; van der Gaag et al., 2013). The growing adoption of the CHR-P 
concept has recently led to the inclusion of the ‘Attenuated Psychosis Syndrome’ into the 
Diagnostic and Statistical Manual-5 appendix as a condition for further study (American 
Psychiatric Association, 2013; Riecher-Rössler & Studerus, 2017). 
Study drop-out and service disengagement in CHR-P patients.  For many years, 
the prediction of psychosis marked the paramount goal of early detection research. However, 
many studies focusing on psychosis prediction reported relatively high attrition rates ranging 
from 13% at 6-9 month follow-up (Lencz et al., 2006), 26% at 18 months (Ruhrmann et al., 
2010), 21-36% at 2 years (Stowkowy et al., 2018; Ziermans, Schothorst, Sprong, & van 
Engeland, 2011), and up to 53-68% at 3 years (Hengartner et al., 2017; Morrison et al., 2007). 
At the same time, many CHR-P patients access research participation via treatment, and 
besides dropping out of studies, often also disengage from clinical services. Currently, the 
reasons for study drop-out and service disengagement in CHR-P patients are largely 
unknown, and it is not yet clear whether CHR-P patients show symptom worsening or 
improvement before study drop-out and service disengagement. As follow-up information 
from these patients is missing, transition to FEP cannot be entirely ruled out, especially as 
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transition to psychosis can occur in the long-term, up to 10 years after initial referral (Nelson 
et al., 2013). In case of a systematic drop-out, i.e. due to symptom remission or worsening, 
the estimation of risk prediction models might be biased. In CHR-P patients with a 
subsequent transition to psychosis, study drop-out and service disengagement might be 
particularly hindering, as symptom progression might further hamper help-seeking and 
service engagement.  
A number of studies have investigated study drop-out and service disengagement in 
FEP patients and found associations with substance abuse or dependence, poor medication 
compliance, history of self-harm or suicidal attempts, lack of insight, lower symptom severity 
at baseline, missing support or involvement of a family member, as well as having milder 
psychopathology and being employed or a student (for systematic review see Doyle et al., 
2014). There are only few prior studies which addressed study drop-out and service 
disengagement in CHR-P patients. While one study could not detect any clinical, functional 
or demographic variables associated with study drop-out (Stowkowy et al., 2018), another 
study reported that higher baseline negative symptoms predicted later study drop-out 
(Hengartner et al., 2017). Stowkowy et al. (2018) additionally assessed a change in symptoms 
over time and reported that both study completers and drop-out patients demonstrated 
significant symptomatic improvement over time. However, this finding has not yet been 
replicated by other studies and it remains unclear whether symptomatic change might occur 
immediately before study drop-out and/or service disengagement. Thus, insight into possible 
predictors and reasons for study drop-out and service disengagement might provide helpful 
information to ensure appropriate treatment and prevent adverse outcomes.  
Clinical and functional long-term outcome of CHR-P patients.  As only a minority 
of patients who fulfill UHR criteria later develop frank psychosis (Fusar-Poli et al., 2016), it 
is necessary to assess outcomes of CHR-P patients without a later transition (CHR-P-NT). 
However, as the cumulative risk of transitioning to psychosis tends to plateau after the third 
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year of initial identification (Kempton, Bonoldi, Valmaggia, McGuire, & Fusar-Poli, 2015), 
most previous studies have followed-up patients for 2-3 years only. A recent study reported 
different trajectories in CHR-P patients, with 43% having favorable outcomes such as 
remission or recovery, and 57% having unfavorable outcomes such as transition, non-
remission, or relapse within one year (Polari et al., 2018). However, only little is known about 
the clinical and functional long-term outcome of CHR-P-NT patients. A recently performed 
systematic review incorporating ten studies with follow-up durations of 2-7.5 years reported 
that 28-71% of CHR-P-NT patients still suffered from subthreshold psychotic symptoms and 
22-82% fulfilled criteria for a non-psychotic mental disorder. The majority of patients also 
suffered from psychosocial impairments (Beck et al., 2019a). As only limited information on 
long-term outcomes in CHR-P-NT patients is available and an evaluation of the predictors of 
long-term clinical and functional outcome is lacking, there is a need to improve the current 
knowledge about the trajectories and long-term outcome of these patients.  
Individualized Metacognitive Training for Psychosis (MCT+) 
Delusions represent core symptoms of schizophrenia and other psychotic disorders. 
They are defined as erroneous beliefs that cannot be corrected despite indisputable contrary 
evidence (American Psychiatric Association, 2013). As previously stated, treatment with 
antipsychotic medication in frank psychosis is associated with only medium effect sizes 
(Leucht et al., 2017) and numerous side effects that can negatively affect treatment adherence 
and medication compliance (Garcia et al., 2016; Lally & MacCabe, 2015). Besides, earlier 
studies reported that antipsychotic treatment might only reduce salience and importance of 
delusions, but not delusional conviction (Mizrahi et al., 2006; Schneider, Jelinek, Lincoln, & 
Moritz, 2011).  
A large body of literature investigating the nature of delusions found that cognitive 
biases are associated with the formation and maintenance of delusional beliefs (Garety & 
Freeman, 2013). Prominent cognitive biases include the jumping-to-conclusions bias (JTC), 
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overconfidence in false judgments, and belief inflexibility/incorrigibility (Garety & Freeman, 
2013; Moritz et al., 2014; Moritz et al., 2017b). The JTC bias is a tendency to make hasty 
decisions and inferences based on limited evidence (Garety & Freeman, 2013), which has 
consistently been reported to be present in patients with delusions and psychotic disorders 
(Garety & Freeman, 2013; So, Siu, Wong, Chan, & Garety, 2016). JTC as well as other 
reasoning biases associated with delusions appear not to be influenced by antipsychotic 
medication (Andreou et al., 2015b; Menon, Mizrahi, & Kapur, 2008; So, Garety, Peters, & 
Kapur, 2010). Thus, there has been growing interest in developing psychological 
interventions complementing antipsychotic treatment for delusions and other positive 
psychotic symptoms.  
MCT+ represents one of these interventions (Andreou et al., 2017; Moritz, Krieger, 
Bohn, & Veckenstedt, 2017a; Moritz, Veckenstedt, Randjbar, & Vitzthum, 2011). It is a 
manualized 12-session intervention, aiming to reduce delusional conviction by raising 
patients’ awareness for the above described cognitive biases associated with delusions. 
Individualized MCT+ represents a further development of the manualized group treatment 
program MCT (Moritz, Veckenstedt, Randjbar, Vitzthum, & Woodward, 2011). However, in 
contrast to group MCT which approaches the metacognitive foundation of delusions with 
predominantly non-delusional scenarios, MCT+ puts a stronger emphasis on individual 
delusional convictions (Andreou et al., 2017) and incorporates techniques adapted from 
Cognitive Behavioral Therapy (CBT). Recent meta-analyses (Eichner & Berna, 2016; Liu, 
Tang, Hung, Tsai, & Lin, 2018; Philipp et al., 2019) of several randomized controlled trials 
have suggested that MCT and MCT+ are effective in the short- and long-term treatment of 
delusions and other positive symptoms. Detailed information on the content and learning aims 
of all the MCT+ modules including cognitive biases can be found in Appendix C.  
Moderators of treatment efficacy in MCT+.  Given the growing focus on 
individualized prediction of patient outcomes in psychiatry, the identification of patients who 
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are more likely to benefit from specialized interventions is of particular importance. Multiple 
studies have assessed predictors of treatment outcomes in CBT oriented interventions 
(O'Keeffe, Conway, & McGuire, 2017) while only one such study has been performed in 
group MCT (Moritz, Menon, Andersen, Woodward, & Gallinat, 2018). Results indicated that 
low baseline self-esteem, social anxiety, and a positive appraisal of the intervention were 
significantly associated with improved short- and long-term outcomes in group MCT 
compared to an active control intervention (Moritz et al., 2018). Moreover, low quality of life, 
high baseline distress and excitement, as well as a lowered decision threshold in the JTC task 
(only at trend-level) predicted better short-term delusional outcome in the MCT group (Moritz 
et al., 2018). However, the findings reported in group MCT might not necessarily generalize 
to individualized MCT+, and to date, no study has yet investigated moderators of treatment 
efficacy in MCT+. Therefore, shedding light on specific moderators of treatment efficacy in 
MCT+ might inform clinical practice and enable to recommend specific criteria for selecting 
patients which benefit most from MCT+. 
Research Questions 
Against this background, the aims of this thesis were 1) to investigate study drop-out 
and service disengagement in CHR-P patients, 2) to assess the clinical and functional long-
term outcome of CHR-P patients without a later transition to psychosis and 3) to explore 
moderators of MCT+ efficacy in patients with psychosis. To examine these research 
questions, the following three original studies have been conducted and published in 
international peer-reviewed journals. The following specific research questions were 
addressed in Articles 1-3 which together constitute this thesis (see appendices D-F).  
Article 1: Predictors of study drop‑out and service disengagement in patients at 
clinical high risk for psychosis (Leanza et al., 2020b). 
- How high is the rate of CHR-P patients who show study drop-out during follow-up and 
who are prone to service disengagement? 
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- What baseline characteristics are associated with study drop-out and service 
disengagement in CHR-P patients? 
- Can certain baseline variables predict study drop-out and service disengagement in this 
population? 
- Did patients show a change in symptoms immediately before study drop-out and service 
disengagement? 
Article 2: Clinical and functional ultra-long-term outcome of patients with a clinical 
high risk (CHR) for psychosis (Beck et al., 2019b).  
- What is the proportion of CHR-P patients who transition to psychosis and how many remit 
from their CHR-P status in the long term? 
- What is the long-term clinical and functional outcome of patients who do not transition to 
psychosis, e.g., regarding subclinical psychotic symptoms, non-psychotic clinical 
symptoms, psychosocial functioning, and overall recovery? 
- Are there any variables predicting clinical and functional outcome in CHR-P-NT patients 
at long-term follow-up?   
Article 3: Moderators of treatment efficacy in individualized metacognitive training 
for psychosis (MCT+) (Leanza, Studerus, Bozikas, Moritz, & Andreou, 2020a). 
- Do variables assessed at baseline moderate the treatment efficacy of MCT+ on delusional 
severity as well as overall positive symptoms relative to an active control intervention with 
no expected effect on positive symptoms? 
Methods 
Setting and Recruitment 
The data for Articles 1 and 2 were collected within the prospective early detection and 
intervention in psychosis (FePsy; Früherkennung von Psychosen) study (Riecher-Rössler et 
al., 2007; Riecher-Rössler et al., 2009), which was conducted in the specialized Center for 
Early Detection and Gender Research at the University of Basel Psychiatric Hospital Basel, 
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Switzerland, between March 2000 and September 2017. Patients suspected to be at risk for 
psychosis were referred to by general practitioners, parents, teachers, and mental health 
professionals. All CHR-P patients meeting inclusion criteria (see Riecher-Rössler et al., 2007) 
were included in the study after providing written informed consent. Additionally, Article 2 
included data from patients recruited via the Bruderholz study. Information about sample 
recruitment and further details concerning the Bruderholz study can be found in Simon et al. 
(2012).  
CHR-P patients were followed up at regular intervals for up to 5 years to examine 
whether transition to psychosis had occurred. From 2000 to 2008, follow-up frequency 
depended upon the estimated risk set. During the first year, high-risk (i.e., APS, BLIPS, 
GRD) patients were assessed monthly, while low-risk patients fulfilling only unspecific risk 
criteria were assessed at 3-month intervals. From 2009 onwards, uniform follow-up 
assessments were provided to all CHR-P patients, and low-risk patients were followed up 
monthly in the same intervals as high-risk patients during the first year. During the second 
and third years, all patients were assessed every 3 months and thereafter annually. During 
follow-up, all patients received treatment according to their needs, clinical case management, 
and supportive counseling. Antipsychotic medication was only initiated after transition to 
psychosis had occurred. In Article 2 all patients who did not transition to psychosis during the 
initial follow-up period were regarded as patients without initial transition and were asked to 
take part in the long-term follow-up assessment. 
The FePsy study was approved by the ethics committee of Northwestern and Central 
Switzerland (EKNZ) and was conducted in accordance with the Declaration of Helsinki. 
Further details concerning the FePsy study design can be found elsewhere (Riecher-Rössler et 
al., 2007; Riecher-Rössler et al., 2009).  
Data for Article 3 were retrieved within the context of a monocentric, rater-blind, 
randomized controlled clinical trial (Andreou et al., 2017) carried out at the Department of 
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Psychiatry and Psychotherapy of the University Medical Center Hamburg-Eppendorf, 
Germany, between January 2013 and July 2015. Patients with non-affective psychotic 
disorders and current or past delusions were recruited among in- and outpatients treated at the 
Psychosis Center of the Department. All patients who met inclusion criteria (see Andreou et 
al., 2017) provided written informed consent before entering the trial. 
In this study, patients were randomized according to a computerized randomization 
plan to either MCT+ or CogPack (Marker, 2003), which is an active cognitive control 
intervention. Treatment allocation was performed observer-blind by a person who was not 
involved in the assessments and intervention delivery. Assessments were carried out at 
baseline, at 6 weeks (T1; 12 intervention sessions completed) and 6 months later (T2). Data 
analyses in this study considered only baseline data and data from T1. All assessments were 
carried out by raters blind to treatment allocation.  
The trial was approved by the Ethics Committee of the German Psychology 
Association. A more detailed description of the overall trial and its main findings can be 
found in Andreou et al. (2017).  
Measures 
In both the FePsy study and the MCT+ original trial, all patients underwent a broad 
entry examination (Andreou et al., 2017; Riecher-Rössler et al., 2007; Riecher-Rössler et al., 
2009). A full description of all measures used in the studies can be found in Articles 1-3 
(Appendices D-F). Here, only the main measures are described.  
Psychopathological assessments.  In Articles 1 and 2 of the FePsy study, all patients 
suspected to be at risk for psychosis were screened using the BSIP (Riecher-Rössler et al., 
2008), which allows the identification of CHR-P and FEP patients (see Appendix B). The 
BSIP has been shown to have a high interrater reliability and predictive validity (Riecher-
Rössler et al., 2008). Positive psychotic symptoms were assessed using the Brief Psychiatric 
Rating Scale Expanded Version (BPRS-E; Lukoff, Nuechterlein, & Ventura, 1986; Ventura, 
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Green, Shaner, & Liberman, 1993). Furthermore, transition to psychosis during follow-up was 
monitored using the four BPRS-E items suspiciousness, unusual thought content, 
hallucinations, and conceptual disorganization. Negative symptoms were assessed with the 
Scale for the Assessment of Negative Symptoms (SANS; Andreasen, 1989). In Article 3 
(MCT+ trial), positive (primarily delusions) and negative symptoms were assessed with the 
Positive and Negative Syndrome Scale (PANSS; Kay, Fiszbein, & Opler, 1987). The PANSS 
is considered as the gold standard assessment in clinical trials (Suzuki, 2011) and has been 
shown to have good psychometric properties (Kay, Opler, & Lindenmayer, 1989).  
Other outcome measures.  In Article 1, study drop-out during follow-up was defined 
as the primary outcome of interest. CHR-P patients were considered as drop-out when no 
contact could be established for at least 1 year after several unsuccessful contact attempts (i.e. 
through phone calls, letters, e-mails). Patients were also considered as having dropped out 
when they explicitly refused to further participate in the study. In this case, drop-out reasons 
were assessed and documented on specific drop-out protocols. In Article 2, remission from 
CHR-P status was considered as one of the main outcomes and was defined as the absence of 
APS or BLIPS, i.e. subthreshold severity scores on all four above-mentioned positive 
symptom items of the BPRS-E (Ventura et al., 1993) for at least 12 consecutive months 
preceding the latest follow-up assessment.  
In Article 3, delusional severity at T1 as measured with the PANSS (Kay et al., 1987) 
was defined as the outcome variable. However, the primary study aim was to assess 
moderators of MCT+ efficacy on delusions and other positive symptoms. The moderator 
variable which assessed the prominent cognitive JTC bias associated with delusions was 
measured with the Fish Task (Moritz, Van Quaquebeke, & Lincoln, 2012), a computerized 
version of the Beads Task (Garety, Hemsley, & Wessely, 1991). In this task, two lakes (A and 
B) containing fish in opposite color ratios are presented. Patients are successively showed 10 
fish in a predetermined sequence. After each draw, patients are asked to estimate the 
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probability that fish originated from lake A and to indicate whether they have made a decision 
regarding the origin of the fish. Parallel versions were used across the testing sessions to 
reduce practice effects. The variables of interest were presence of the JTC bias (defined in a 
dichotomous fashion as decisions based on only one or two fish) and the probability threshold 
at decision (i.e. the minimum probability estimate at which a decision was made in favor of 
the respective lake; a higher probability threshold indicates more cautious inference making). 
Other moderator variables included in the study can be found in Article 3 (Appendix F).  
Statistical analyses.  All statistical analyses of Articles 1-3 were conducted using the 
R environment for statistical computing (R Development Core Team, 2019).  
Article 1 investigated baseline predictors of study drop-out and service disengagement 
in CHR-P patients, while Article 2 examined baseline predictors for remission from CHR-P 
and transition to psychosis. Analyses in Article 2 were conducted in two different samples, 
namely the initial baseline sample of all CHR-P patients and the sample of CHR-P-NT 
patients who participated in the long-term follow-up assessment. According to the FePsy 
study design, follow-up assessment could be ceased due to various events, and CHR-P 
patients could only experience one of the event types over follow-up. Therefore, competing 
risk survival models were used and different competing events were defined for Article 1 and 
2. In Article 1, study drop-out and transition to psychosis were considered as competing 
events. Univariable models were fitted for each baseline predictor variable of study drop-out. 
Study inclusion date (i.e. inclusion from 2000-2008 vs. inclusion from 2009-2017) was 
included as a binary predictor because of the previously described methodological changes in 
study design in 2009 concerning the frequency of follow-up intervals. To investigate whether 
symptoms changed immediately before study drop-out, dependent sample t-tests were 
applied. The rates of study drop-out and transition to full-blown psychosis over the whole 
course of the 5-year follow-up were assessed using cumulative incidence curves (CIC), which 
are the competing risks analogs of Kaplan-Meier survival curves (Kleinbaum & Klein, 2012). 
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CIC curves were also used in Article 2, where remission from CHR-P and transition 
rates over the whole 16-year follow-up period were analyzed in the initial sample. Competing 
risks survival analyses were again conducted to investigate baseline predictors for remission 
from CHR-P status and transition to psychosis, using univariable models for each predictor 
variable. Here, remission from CHR-P was regarded as the primary outcome of interest, while 
transition to psychosis was regarded as the competing event. Besides, in the second sample of 
CHR-P-NT patients logistic and multiple regression analyses were conducted to examine the 
predictive value of baseline sociodemographic and clinical variables regarding both remission 
from CHR-P status and psychosocial functioning at long-term follow-up. 
In Article 3, linear mixed-effects models were applied to investigate potential 
moderators of MCT+ efficacy on delusions and other positive symptoms. For each moderator 
variable, one mixed-effects model was fitted that included group (MCT+ vs. CogPack), time 
(baseline vs. T1), and the corresponding moderator variable, as well as all possible two and 
three-way interactions, as fixed effects factors. Additionally, the models included an intercept 
that randomly varied per subject.  
Detailed descriptions of all statistical analyses can be found in Articles 1-3 
(Appendices D-F). 
Summary of the Results 
Predictors of study drop out and service disengagement in patients at clinical high risk 
for psychosis 
Data of 200 patients were analyzed. Within 5 years, 53 patients (36%) dropped out of 
the study and 43 (28%) transitioned to psychosis. As nearly all patients who had dropped out 
also disengaged from the clinical service, study drop-out was used as a proxy for service 
disengagement. 41 (77.4%) of patients with study drop-out explicitly requested to discontinue 
the follow-up assessments. One of the main reasons identified was being annoyed by requests 
for study participations (19.5%). Patients with more severe baseline disorganized symptoms 
and a late study inclusion (2009-2017) were significantly more likely to drop out and 
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disengage. No other baseline sociodemographic or clinical variables significantly predicted 
study drop-out. Immediately before drop-out, a significant improvement in negative 
symptoms was observed. There were no significant differences in positive symptoms. For 
detailed results, see Appendix D.  
Clinical and functional ultra-long-term outcome of patients with a clinical high risk for 
psychosis 
From the original sample of 255, 60 patients transitioned to psychosis. At 5-, 10-, and 
15-year follow-up, the estimated cumulative transition rates were 31%, 35%, and 38%. The 
proportion of patients with remission from CHR-P status within the first 2, 3, 4, and 5 years of 
follow-up was estimated as 24%, 33%, 36%, and 37%, respectively. Ten years after baseline, 
an estimated proportion of 51% had remitted, with no further remissions after that time point. 
Results indicated that higher baseline psychosocial functioning was associated with a higher 
remission rate in the original sample. Other baseline variables such as age, 
psychopathological symptoms, or cannabis use were not significantly associated with 
remission. Of the 72 CHR-P-NT patients reassessed at long-term follow-up, 60 (83%) had not 
transitioned to psychosis. Of these, 51 (85%) had remitted from their high risk state, 39 (65%) 
had no axis I diagnosis, but only 17 (28%) had fully recovered clinically and functionally. No 
significant associations between baseline variables and remission from CHR-P status at long-
term follow-up were found. See Appendix E for more information on results.  
Moderators of treatment efficacy in individualized metacognitive training for psychosis  
In MCT+ relative to CogPack (active control intervention) the presence of the 
jumping-to-conclusions bias, a lowered decision threshold in the Fish Task, and low baseline 
self-esteem were associated with larger improvements in delusional severity and/or overall 
positive symptoms over time. Other moderator variables such as subjective attitudes towards 
psychosis, cognitive insight, quality of life, or selective attention, did not moderate the 
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treatment efficacy of MCT+ relative to CogPack. For a detailed description of the results, see 
Appendix F.  
Discussion 
Suffering from a CHR-P status or a full-blown psychotic disorder often has a 
significant impact on a person’s life. Psychotic symptoms in both patient groups are often 
accompanied by functional deterioration and high burden. To improve the outlook and 
maximize the chances of remission for those affected, both early detection and intervention 
research, as well as the development of new treatment approaches are indispensable. This 
dissertation therefore aimed to address several unresolved and scarcely investigated research 
questions regarding social psychiatric and treatment related outcomes in the spectrum of 
psychotic disorders.  
Findings of the early detection and intervention studies 
In Article 1, patients with more severe baseline disorganized symptoms and a late 
study inclusion (2009-2017) were significantly more likely to drop out. A significant 
improvement of negative symptoms was observed immediately before study drop-out and 
service disengagement. In Article 2, 51% of patients remitted from the CHR-P status within 
15 years. In patients with a long-term follow-up assessment, the remission rate was 85%, but 
only 28% showed full clinical and functional recovery. Higher baseline psychosocial 
functioning was associated with a greater likelihood of remission from CHR-P status during 
follow-up.  
Compared to other studies which reported study drop-out rates in CHR-P patients 
(Hengartner et al., 2017; Stowkowy et al., 2018), the rather low drop-out and disengagement 
rate of 36% reported in Article 1 might be attributed to methodological differences regarding 
its operationalization. To date, a clear consensus on the definition of service disengagement is 
still lacking and a dynamic, multidimensional approach incorporating different dimensions of 
engagement and disengagement is warranted (Tindall, Francey, & Hamilton, 2015). 
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The association between study inclusion date with drop-out and disengagement might 
be attributed to changes in the study design applied in 2009 described above (see Methods). 
Due to the long recruitment span in the FePsy study, confounding factors might have 
impacted this result. For example, in 2011 a weekly e-mail reminder system was implemented 
to facilitate the management of follow-up time points for caregivers. Besides, from 2011 
onwards, patients were asked to participate in further multicenter studies in addition to the 
FePsy project. Both might have resulted in patients being contacted more often and in shorter 
intervals. Thus, contacting patients too often or burdening them with too many assessments 
might have led to unintended effects, such as patients being annoyed and therefore 
disengaging from the clinical service and dropping out of study assessments. In line with this, 
some patients did indeed declare being annoyed by requests for study participations. 
Overall, the findings of Article 1 indicate that patients who drop out and disengage 
from the clinical service do not suffer from more severe psychopathological symptoms. This 
is in line with Stowkowy et al. (2018), who reported symptomatic improvements in patients 
with drop-out over time. As positive symptoms did not significantly worsen immediately 
before drop-out, it appears unlikely that patients who discontinue study follow-up and leave 
clinical service do so because of increased positive symptoms or transition to psychosis. The 
reported improvement of negative symptoms immediately before drop-out and disengagement 
might rather be associated with better psychosocial functioning, which might have lowered 
the need for treatment and increased the likelihood of dropping out. Hence, it may be 
suggested that the follow-up duration and the proposed 5-year model of care might have been 
too long and overly pathologizing for patients experiencing symptomatic improvements. 
Thus, some patients might no longer require clinical service treatment and might be 
discharged to other models of care depending on their symptomatology. However, positive 
symptoms remained relatively stable between the second-last and last assessment, suggesting 
that some patients might still suffer from subthreshold psychotic symptoms at the time of 
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drop-out and disengagement. The findings in Article 2 demonstrated that some patients still 
transition to psychosis in the long-term and that only a minority of CHR-P-NT patients had 
fully recovered clinically and functionally at long-term follow-up. This leads to the question 
of how to possibly adapt the clinical care to individual patient needs in order to strike the 
balance between capturing late transitions and not imposing a burden on patients. Hence, it 
might be prudent to individually tailor the frequency and length of follow-ups according to 
the symptom severity. Individualized risk calculators (Cannon et al., 2016; Fusar-Poli et al., 
2017; Malda et al., 2019) implementing multivariable risk factors may facilitate treatment 
planning accordingly. However, until now the implementation of these tools into clinical 
practice is still lacking. Finally, creating a greater incentive for patients to further participate 
in follow-up assessments might minimize study drop-out. Offering follow-up assessments via 
telephone, video calls, or online questionnaires, and reducing questions to transition-relevant 
items might facilitate participation for patients. Further, highlighting the value of study 
participation and offering a small reimbursement (e.g. vouchers) might increase patients’ 
motivation for follow-up assessments.  
The FePsy study has examined a variety of clinical and sociodemographic variables. 
Yet, in both Articles 1 and 2 only little evidence of predictors for study drop-out, service 
disengagement, and remission was found. On one hand, the rather modest sample sizes of 
patients with study drop-out (n = 53 vs. 147 without drop-out) and patients without remission 
in the long-term follow-up sample (n = 9 vs. 51 with remission), might have reduced the 
power to detect small effects. On the other hand, factors associated with transition might play 
a less important role with regard to these specific outcomes. Eventually, other factors not 
assessed in the FePsy study might play a greater role concerning study drop-out, service 
disengagement, and remission. A good therapeutic relationship and working alliance with the 
caregiver has earlier been described as a common factor for symptom reduction and 
improvements in quality of life within the frame of psychotherapy (Wampold & Budge, 
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2012). Thus, a therapeutic bond that is characterized through trust, feelings of empathy, and 
belongingness may enhance engagement of patients needing clinical care and may further be 
associated with remission from CHR-P status. Moreover, expectations of success and self-
efficacy or feelings of disempowerment and dissatisfaction with the service, reported to 
influence engagement in FEP patients, might influence service disengagement in CHR-P 
patients as well (Lal & Malla, 2015; Tindall et al., 2015). Alternatively, remission from CHR-
P status might rather be associated with protective rather than risk factors. Patients with better 
baseline psychosocial functioning may be more resilient and feature more internal and 
external protective resources such as supportive relationships and a stable educational or work 
environment. However, it might be difficult to predict study drop-out, service disengagement, 
and remission based on information obtained at service entry only. Models incorporating 
information obtained during follow-up might be needed to predict these outcomes with 
sufficient accuracy. Thus, further studies are needed to comprehend which factors and 
mechanisms might contribute to study drop-out, service disengagement, and remission.  
Findings of the MCT+ study trial 
In Article 3, patients who were prone to the jumping-to-conclusions bias at baseline 
showed a stronger decrease of delusional symptoms and positive symptoms after 6 weeks 
following MCT+ than CogPack. The only available study that explicitly assessed moderators 
of treatment efficacy in group MCT (Moritz et al., 2018) could not demonstrate this 
association. However, this contrasting finding may be attributed to differences in the follow-
up duration between the studies (6-week follow up vs. 6-month and 3-year follow-up) as well 
as setting related differences in the delivery of the intervention (individualized vs. group 
format). Additionally, a lower decision threshold, as well as low baseline self-esteem, were 
associated with larger improvements in the MCT+ compared to the CogPack intervention. 
These results are in line with Moritz et al. (2018), who found that low baseline self-esteem 
predicted improved outcomes in group MCT relative to CogPack and that a lowered decision 
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threshold moderated treatment efficacy in patients participating in group MCT for delusional 
severity at a trend level.  
The reported results in Article 3 are consistent with the aim of MCT+ to improve 
delusions as well as positive symptoms by improving cognitive biases. It has previously been 
demonstrated that jumping-to-conclusions can be reduced by improving neurocognitive 
performance following a cognitive remediation intervention such as CogPack (Andreou et al., 
2015a). However, this does not necessarily translate into a decline in delusional severity. 
Andreou et al. (2015a) reported that both patients partaking in group MCT and CogPack 
showed improvement in jumping-to-conclusions over time. However, improvements in 
jumping-to-conclusions were only associated with a reduction in delusion severity in the 
MCT group. Thus, the specific mechanism of action concerning delusional improvement in 
MCT and MCT+ might be attributed to its core element, namely the explicit education on 
cognitive biases and on the importance of adequate evidence gathering before reaching a 
conclusion.  
As patients prone to the jumping-to-conclusions bias displayed the greatest 
improvements in delusions and positive symptoms, it would be valuable to analyze whether 
other cognitive biases associated with delusions such as the bias against disconfirmatory 
evidence (Eisenacher & Zink, 2017; McLean, Mattiske, & Balzan, 2017; Woodward, Moritz, 
Cuttler, & Whitman, 2006) or overconfidence in false memories and errors (Balzan, 
Woodward, Delfabbro, & Moritz, 2016; Moritz et al., 2009; Moritz & Woodward, 2006) 
might as well moderate treatment efficacy of MCT+. Also, other factors such as treatment 
satisfaction or, as proposed by Moritz et al. (2018), self-efficacy and motivation to change 
might possibly impact treatment efficacy of MCT+. However, as this was the very first study 
investigating moderators of individualized MCT+, further studies are needed to draw firm 
conclusions on which patients might maximally benefit from MCT+.  
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Previous cognitive models have assigned a major role to cognitive biases in the 
pathogenesis of psychosis, contributing to delusion formation and persistence (Garety & 
Freeman, 2013). Especially the jumping-to-conclusions bias seems to be an early cognitive 
marker of emerging psychosis, which has been found to be present in CHR-P patients 
(Rausch et al., 2016). Thus, CHR-P patients who present with the jumping-to-conclusion bias 
suffering from APS or BLIPS might benefit from the content of group MCT and/or 
individualized MCT+ similarly as patients with psychosis. However, the effects of MCT on 
subthreshold psychotic symptoms have not yet been investigated. Unfortunately, a pilot study 
planned and organized at the University of Basel Psychiatric Hospital on the effects of MCT 
in a mixed group of CHR-P and FEP patients had to be terminated due to recruitment issues 
and high study drop-out.  
Strengths and Limitations 
To the best of knowledge, this thesis assessed predictors of study drop-out and service 
disengagement in CHR-P patients as well as predictors of clinical and functional long-term 
outcome in CHR-P patients without transition to psychosis for the first time. Also, the 
assessment of moderators of individualized MCT+ is so far unique. Strengths of this thesis 
were: (1) The longitudinal study design and the very long observation period of up to 16 years 
used in Articles 1 and 2, which allowed to investigate outcomes and predictors thereof in the 
long-term; (2) the application of competing risks survival models in Articles 1 and 2, which 
allowed to take into account both the primary outcome of interest (i.e. study drop-out, 
remission), the time to event as well as the competing event (i.e. transition to psychosis); (3) 
the assessment of CHR-P patients with the BSIP, which has been shown to have a high 
reliability and validity; (4) the randomized controlled trial design of Article 3, which is 
regarded as the gold standard of efficacy evaluations and allowed to control for potentially 
confounding variables; (5) the assessment of full-blown psychotic symptomatology with the 
reliable and valid PANSS. 
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Some limitations should be considered regarding this thesis: (1) In Articles 1, 2 and 3 
analyses were not controlled for multiple testing, which might have led to chance effects and 
false-positive findings, possibly impacting internal and external validity. However, as 
analyses were of exploratory nature, correction for multiple testing might have increased type 
II errors limiting the capacity to detect important predictors and moderators; (2) the samples 
of Articles 1, 2 and 3 consisted of patients who were mostly referred to the clinical service, 
which might have led to a selection bias possibly affecting the external validity of the results. 
Assumptions for patients who never reached clinical service, such as for example homeless 
people at-risk for psychosis or with a full-blown psychotic episode, cannot be made; (3) the 
rather modest number of patients with study drop-out in Article 1 or without remission in 
Article 2 might have limited the statistical power to detect significant outcome predictors. 
Outlook 
To further explore predictors of study drop-out, service disengagement and long-term 
outcome in CHR-P patients, multivariable predictor models encompassing multiple domains 
should be considered. In addition, predictor models might include protective factors such as 
therapeutic alliance or feelings of self-efficacy and not solely focus on variables associated 
with transition to psychosis. Further studies on the validation of individual risk prediction 
tools are needed to implement these tools into clinical practice and ensure individual 
treatment planning. Additional studies assessing moderators of treatment efficacy in group 
MCT and individualized MCT+ are warranted to provide specific criteria for selecting 
patients for whom the intervention is most appropriate. At the same time, further 
investigations are needed to clarify whether the implementation of an MCT based intervention 
in CHR-P patients might be an effective treatment method in emerging psychosis. 
Conclusions 
In conclusion, this thesis provides new insights on important research questions 
regarding social psychiatric and treatment related outcomes in the spectrum of psychotic 
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disorders. The findings underline the importance of individualized risk assessment and 
treatment care in CHR-P patients and suggest that the question concerning predictors of study 
drop-out, service disengagement, and remission are not yet sufficiently answered. Thus, 
future studies should replicate and extend the current findings to investigate whether other 
predictor variables might be associated with these outcomes. Additionally, this dissertation 
points out that those patients with psychosis who are prone to the jumping-to-conclusions bias 
and have low self-esteem particularly benefit from the theory-driven MCT+ intervention. This 
could be considered as a starting point for future research on which patients might particularly 
benefit from MCT+. 
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Appendix A 
Model of Psychosis Onset from the Clinical High Risk State  
Figure A1. Assumed natural history of the high risk state and model of psychosis onset suggested by Fusar-Poli 
et al. (2013). The higher the line on the y-axis, the higher the symptom severity.  
 
Basic symptom criterion: Subtle and subclinical disturbances in drive, stress tolerance, 
affect, thinking, speech, perception and motor action. The disturbances are self-experienced 
by the patient, with full insight into their abnormal nature (Schultze-Lutter et al., 2007).  
Functional state - biological trait criterion: Family history of psychosis (first-degree 
relatives) and/or presence of schizotypal personality disorder, combined with a significant 
functional decline. 
Attenuated positive symptoms: Subthreshold positive symptoms, often subthreshold in 
either intensity and/or frequency persisting over 1 week. 
Brief limited intermittent psychotic episode: Transient, full-blown psychotic symptoms 
which last no longer than 1 week with spontaneous remission.  
Definition of the different risk categories vary slightly depending on the instrument 
used for risk assessment (see Fusar-Poli et al., 2013 for further details).  
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Appendix B 
Ultra-High Risk and First-Episode Psychosis Criteria According to the Basel Screening 
Instrument for Psychosis Used in the Basel FePsy Study 
 
Table B1 
Inclusion Criteria for Clinical High Risk for Psychosis and First-Episode Psychosis 
Patients 
Clinical High Risk for 
Psychosis 
(CHR-P) 
a) Attenuated Psychotic Symptoms (APS) 
Current (now or in the last 14 days) attenuated psychotic (pre-psychotic) 
symptoms, defined by a score of  
- 3 - 4 on the BPRS “Suspiciousness” scale or 
- 2 - 3 on the BPRS “Hallucinations” scale or  
- 3 - 4 on the BPRS “Unusual Thought Content” scale 
- appearance at least several times per week 
- in total persisting for > 1 week 
 
and / or 
 
b) Brief Limited Intermittent Psychotic Symptoms (BLIPS) 
Previous (more than 14 days ago) shown transient isolated psychotic 
symptoms, at least one of the following symptoms, defined by a score of 
- 4 or more on the BPRS “Hallucinations” scale or 
- 5 or more on the BPRS “Unusual Thought Content” or 
- 5 or more on the BPRS “Suspiciousness” scale or 
- 5 or more on the BPRS “Conceptual Disorganization” scale 
- in total persisting < 1 week 
- spontaneous remission  
 
and / or 
 
c) Genetic Risk Category Combined with Potential Prodromes  
- Psychosis in first-degree relative plus at least 2 or more risk factors 
from the BSIP (Items 1-18) or  
- Suspected psychosis in first-degree relative or confirmed psychosis 
in second-degree relative plus at least 1 highly specific and at least 2 
or more risk factors  
 
and / or 
 
d) Unspecific Risk Category 




Current psychotic transition, at least one of the following symptoms 
- 4 or more on the BPRS “Hallucinations” scale or 
- 5 or more on the BPRS “Unusual Thought Content” or 
- 5 or more on the BPRS “Suspiciousness” scale or 
- 5 or more on the BPRS “Conceptual Disorganization” scale 
- appear more than once a week, for > 1 week 
 
Note. BPRS = Brief Psychiatric Rating Scale. In the Basel Screening Instrument for Psychosis, CHR-P 
patients are synonymously referred to as at-risk mental state patients (ARMS). Highly specific risk factors: 
Items 1-18 of the instrument indicated with an asterisk. A highly specific risk factor can be replaced by 2 
unspecific risk factors (Items 1-18 without asterisk). See Peralta et al. (2019) for an English version of the 
instrument with all items.  
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Appendix C 
Individualized Metacognitive Training for Psychosis 
Content and Learning Aims 
 
Table C1 




Content Learning Aims 
1 Building a meaningful therapeutic relationship, assessment of case history. 
- Assessment of current and past symptoms and illness 
course 
- Clarification of motivational aspects 
2 Introduction to the MCT+ program. 
- Basic introduction 
- Definition “Metacognition” 
- Goal assessment 
3 
Elaboration of an individual case 
formulation. 
- Development of a vulnerability-stress model 
4* 
Attributional style, monocausal 
inferences 
In patients with psychosis, a tendency to 
make one-sided explanations for the 
occurrence of a specific situation has 
been observed. For example, making 
external attributions (blaming others) for 
negative events or failures. 
- Illustrate that one-sided attributions might promote 
misinterpretations possibly leading to interpersonal 
problems or conflicts 
- Encourage the consideration of different factors (e.g., 
circumstances, others, myself), which might 
simultaneously contribute to the outcome of an event 
5* 
Jumping-to-conclusions and decision 
making 
Patients with psychosis tend to make 
hasty decisions without enough 
background information.  
- Demonstrate associations between jumping-to-
conclusions and anxiety, feelings of threat and 
avoidance behavior 
- Invite the patient to consider and gather as much 
information as possible before making a decision 
6* 
Uncorrectable beliefs, bias against 
disconfirmatory evidence  
A tendency to continue to cling to an 
opinion or belief, even when confronted 
with information that speaks against it.  
- Tunnel vision can lead to interpersonal problems and 
may obstruct a realistic appraisal of a situation 
- Discuss possible consequences of tunnel vision 
together with the patient 
- Work on cognitive flexibility, encourage an exchange 
with trustworthy friends or family 
7* 
Theory of mind and empathizing 
Deficits in Theory of Mind have been 
observed in patients with psychosis, e.g., 
difficulties in detecting and evaluating 
facial expressions of others, or inferring 
motives of others from their ongoing 
behavior. 
- Evaluation on how to make more reliable 
interpretations in social situations 
- Exercise emotion recognition 
- Discuss implicit social laws (courtesy, dress codes, 
manners) 
- Remind the patient to draw firm conclusions about 
another person only if the person is well-known 
8* 
Memory and overconfidence in false 
memories 
Patients with psychosis suffer from 
memory deficits. Patients are more 
confident in their false memories, but 
confidence in true memories can be 
decreased.  
- Discussion of possibly reduced ability to differentiate 
between true and false memories  
- Presentation of heuristics to discriminate true from 
false memories (e.g., true memories are often more 
vivid) 
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9 
Depression and thinking 
Patients may suffer from thinking biases 
that might promote comorbid depressive 
symptoms. 
- Illustrate important association between thoughts, 
feelings and behavior 
- Sensibilization for depressive thinking biases and 
thoughts and behavioral consequences like social 
withdrawal, feelings of loneliness and depression 
- Support in planning mood-enhancing activities,  
- Tips to improve and stabilize mood, dealing with 
ruminating thoughts  
10 
Self-esteem 
Psychotic symptomatology may have 
long-term negative consequences on 
patients’ self-esteem. 
 
- Discussion of positive and negative effects of 
psychosis on self-esteem  
- Observable and not directly observable characteristics 
of a healthy self-esteem 
- Communication of specific strategies to improve self-
esteem and application to everyday life 
11 
Living with psychosis and relapse 
prevention 
How to deal with the diagnosis and 
stigmatization, which might be 
associated with the disorder. Prepare an 
individual plan for relapse prevention.  
- Learning how to communicate the disorder to others 
- Explanation of symptoms and of how to correct false 
information or stereotypes about the disorder 
- Importance of stress reduction concerning relapse 
prevention 
- Individual list with early warning signs and 
emergency plan 
12 
Hearing voices (optional) 
Education and information about hearing 
voices.  
- Analyze own voice hearing, investigate possible 
triggers and maintaining factors 
- Assessment of own (problematic) thoughts about 
hearing voices and analyze whether these might 
reinforce voice hearing due to stress and burden 
- Encourage to try out different strategies to deal with 
hearing voices  
Note. Therapy units marked with an asterisk focus on prominent cognitive biases associated with the formation 
and maintenance of delusional beliefs. For more detailed information see Moritz et al. (2017a). All therapy units 
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Abstract
Purpose Study drop-out during follow-up and service disengagement frequently occur in patients at clinical high risk for 
psychosis (CHR-P). However, little is known about their predictors. Therefore, we aimed to analyze the rate and reasons 
for drop-out and service disengagement in CHR-P patients and investigate their sociodemographic and clinical predictors.
Methods Data from 200 patients of the prospective Früherkennung von Psychosen (FePsy) study were analyzed with com-
peting risks survival models, considering drop-out and transition to psychosis as competing events. To investigate whether 
symptoms changed immediately before drop-out, t tests were applied.
Results Thirty-six percent of patients dropped out within 5!years. Almost all drop-outs also disengaged from our service. 
Hence, study drop-out was used as a proxy for service disengagement. Patients with more severe baseline disorganized 
symptoms and a late inclusion into the study were significantly more likely to disengage. Immediately before disengagement, 
there was significant improvement in negative symptoms only.
Conclusion A considerable proportion of CHR-P patients disengaged from our clinical study and service. Patients who 
were included during a later study period with more assessments disengaged more often, which might have been due to 
more frequent invitations to follow-up assessments and thereby increasing participation burden. Hence, our study provides 
a cautionary note on high-frequency follow-up assessments. Larger-scale studies evaluating predictors on multiple domains 
would help to further elucidate drop-out and disengagement.
Keywords Attrition!· Service use!· Clinical service!· At-risk mental state!· Early intervention
Introduction
Psychotic disorders such as schizophrenia are serious mental 
disorders, which occupy the sixth largest share of disabil-
ity-adjusted life years (DALYs) in European adults [1, 2]. 
Schizophrenia is associated with high premature mortal-
ity rates leading to about 15!years of potential life lost and 
increased rates of multiple somatic disorders [3, 4]. In the 
last decades, there has been growing interest in the early 
detection and intervention regarding psychotic disorders, as 
it has been shown that early treatment can improve outcomes 
in those a"ected [2, 5]. Even patients at clinical high risk 
for psychosis (CHR-P) may su"er from a high symptomatic 
burden and functional decline [for meta-analysis, see 6]. 
The establishment of CHR-P services has shown that early 
detection and intervention is beneficial to this patient group 
in many respects. Specifically, it has been associated with 
symptom reduction, improvement of functional outcomes 
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and a reduction of the risk of transition to frank psychosis 
[2, 5, 7].
However, an unresolved issue in studying CHR-P patients 
is that a considerable proportion of these patients drop out 
during the study follow-up. Recent studies reported drop-out 
rates ranging from 36% at 2!years of follow-up [8] to 68% at 
3!years [9]. Only few studies investigated predictors of study 
drop-out and those existing reported inconsistent results. 
While one study reported that higher baseline negative 
symptoms significantly predicted later study drop-out [9], 
another study could not detect any significant relationship 
between baseline clinical variables and later study drop-out 
[8]. However, in both studies, sociodemographic and clini-
cal variables such as age, gender, marital status, ethnicity, 
positive psychotic or depressive symptoms, social and role 
functioning, antipsychotic or antidepressant medication, as 
well as years of education were not associated with study 
drop-out [8, 9].
At the same time, many CHR-P patients disengage from 
clinical early intervention services. It has previously been 
described that service disengagement may be associated 
with poorer outcomes and higher health care costs across 
mental health services [10, 11]. To our knowledge, only one 
study has explicitly focused on service disengagement in 
CHR-P patients [12]. In this study, data on patients referred 
to the Outreach and Support in South London (OASIS) 
were collected indirectly from clients’ general practitioners 
and electronic patient files. It was found that over one-fifth 
(21.2%) of referred patients did not attend or engage with 
the service. Furthermore, those who did not engage with the 
clinical service were more often unemployed at the time of 
referral than engagers [12]. No di"erences with regard to 
ethnicity, age, gender, or marital status were found.
While only few studies have investigated predictors 
of service disengagement and study drop-out in CHR-P 
patients, a number of studies have been performed in first 
episode psychosis (FEP) patients [for systematic review, see 
13], which might provide further indications for potential 
predictors in CHR-P patients. Studies analyzing service 
disengagement in FEP patients found that disengagement 
was significantly predicted by substance abuse or depend-
ence [13–15], poor medication compliance [14, 16], history 
of self-harm or suicidal attempts [14], lack of insight [13], 
lower symptom severity at baseline [13, 15], missing sup-
port or involvement of a family member [13], as well as 
having milder psychopathology, and being employed or a 
student [15]. Conflicting findings have been reported regard-
ing duration of untreated psychosis (DUP), since shorter as 
well as longer DUP [13, 14] has been associated with service 
disengagement.
There are still several open questions regarding service 
disengagement and/or study drop-out in CHR-P patients. 
So far, it is not clear if some of the factors associated with 
service disengagement in FEP patients (e.g., substance 
abuse/dependence or lack of illness insight) are also associ-
ated with service disengagement in CHR-P patients. Further-
more, it is unknown whether patients who disengage from 
services show symptom worsening or improvement imme-
diately before service disengagement and/or study drop-out.
Thus, the present study aimed to analyze the rate, self-
reported reasons and predictors for service disengagement 
and/or study drop-out in CHR-P patients. Due to our study 
design, we were able to analyze predictors of both service 
disengagement and study drop-out at the same time, as these 
two outcomes were highly correlated in our study. Specifi-
cally, we aimed to replicate previous findings and examine 
additional predictors of service disengagement which have 
previously not been analyzed in this patient group. Based 
on previous studies in FEP patients, we hypothesized that 
lack of insight and cannabis use would significantly predict 
service disengagement in CHR-P patients. Additionally, we 
hypothesized that clinical variables would possibly predict 
service disengagement. We especially tested if service dis-
engagement is associated with recent change in symptoms.
Materials and!methods
Setting and!recruitment
Study participants were recruited between March 1, 2000 
and May 31, 2017 within the prospective “Früherkennung 
von Psychosen” (FePsy; early detection of psychosis) study. 
A detailed description of the overall study design can be 
found elsewhere [17, 18]. Recruitment took place via the 
FePsy Clinic, University of Basel Psychiatric Hospital, Swit-
zerland, where patients suspected to be at risk for psychosis 
were referred to by general practitioners, parents, teachers, 
as well as mental health professionals. All patients referred 
to our service and meeting inclusion criteria (see below) 
were asked to participate in our prospective study. All study 
participants provided written informed consent. The study 
was approved by the ethics committee of Northwestern and 
Central Switzerland (EKNZ) and was conducted in accord-
ance with the Declaration of Helsinki.
Screening
CHR-P patients were identified using the Basel Screening 
Instrument for Psychosis (BSIP), which is a semi-structured 
interview developed by Riecher-Rössler et!al. [19]. The 
BSIP allows the identification of CHR-P or FEP patients. It 
is composed of the prodromal symptoms of the Diagnostic 
and Statistical Manual of Mental Disorders [DSM-III-R; 20], 
other risk factors such as young age or drug abuse derived 
from previous studies [19, 21], and the Personal Assessment 
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and Crisis Evaluation (PACE) criteria by Yung et!al. [22]. 
Additionally, the BSIP defines an unspecific risk category 
(URC) for patients thought to be at lower risk because of 
presenting with less specific symptoms and risk factors for 
psychosis. The instrument has been shown to have a high 
reliability and predictive validity [18, 19]. A more detailed 
description of the BSIP as well as an English version of the 
instrument can be found in Peralta et!al. [23].
Patients were included in this study if they met CHR-P 
criteria according to the BSIP, which occurred if one of the 
following criteria was met: (1) attenuated psychotic symp-
toms (APS); (2) brief limited intermittent psychotic symp-
toms (BLIPS); (3) genetic risk and deterioration syndrome 
(GRD): genetic risk in combination with two or more other 
risk factors such as social decline; and (4) URC: a combi-
nation of risk factors according to the BSIP, which can be 
found in Peralta et!al. [23]. Patients fulfilling the criteria for 
APS, BLIPS or GRD are considered at “high risk” because 
of presenting a more psychosis-related risk set; whereas, 
patients fulfilling the URC criteria were considered at “lower 
risk” because of the unspecific nature of their symptoms 
[17, 19, 23].
Exclusion criteria were: age < 18, insu#cient knowl-
edge of German, IQ < 70, current or previous episode of 
schizophrenic psychosis according to the BSIP criteria (i.e., 
transition criteria according to Yung et!al. [22] fulfilled), 
antipsychotic treatment for > 3!weeks (lifetime) and/or a 
total amount of $ 2500!mg chlorpromazine equivalent, or 
psychotic symptomatology within a clearly diagnosed a"ec-
tive psychosis or borderline personality disorder [17].
Baseline assessments
Sociodemographic variables and illness insight were 
assessed with the Basel Interview for Psychosis [BIP; 24], 
a semi-structured interview designed to assess indicators of 
emerging psychosis and the temporal development of psy-
chiatric symptoms over the entire life span. Illness insight in 
the BIP was categorically rated as “absent”, “fully present”, 
or “questionable”.
Baseline negative symptoms were assessed with the Scale 
for the Assessment of Negative Symptoms [SANS; 25]. The 
SANS total score and its five original subscales (i.e., a"ec-
tive flattening, alogia, avolition/apathy, asociality/anhedonia 
and inattention) were used for statistical analyses. Baseline 
psychotic symptoms were assessed with the Brief Psychi-
atric Rating Scale Expanded version [BPRS-E; 26], and 
BPRS-E subscales were calculated according to the five-fac-
tor structure (positive symptoms, negative symptoms, acti-
vation, a"ect and disorganization) proposed by Shafer et!al. 
[27]. Functioning was measured with the Global Assessment 
of Functioning (GAF) scale [28]. To assess comorbid psy-
chopathology, we applied the Structured Clinical Interview 
for DSM-IV Axis I Disorders [SCID-I; 29] and additionally 
applied the SCID-II for personality disorders if screening 
was positive [30].
Follow-up assessments
CHR-P patients were reassessed and followed up at regular 
intervals for up to 5–7!years to examine whether transition 
to psychosis had occurred. However, since only few patients 
had a follow-up duration of more than 5!years, these patients 
were treated as right-censored at the 5-year follow-up. From 
2000 to 2008, follow-up frequency depended upon the esti-
mated risk set. Specifically, during the first follow-up year, 
“high-risk” patients were assessed monthly, while “low-risk” 
patients fulfilling only the URC criteria were assessed at 
3-month intervals. During the second and third follow-up 
years, all patients were assessed every 3!months and thereaf-
ter annually. In the year 2009, methodological changes were 
applied to the FePsy study. To provide uniform follow-up 
assessments to all CHR-P patients, “low-risk” patients were 
followed up in the same intervals as “high-risk” patients and 
were also assessed monthly during the first follow-up year. 
Assessment intervals during the second and third years did 
not change.
During follow-up, all patients received supportive coun-
seling and clinical management. A small fraction (n = 9) of 
the included patients also participated in the Neurapro study 
[31, 32] and thus were treated with omega-3 fatty acids or 
placebo. Transition to psychosis was monitored applying the 
transition criteria of Yung et!al. [22] using the four BPRS 
items “suspiciousness”, “unusual thought content”, “hal-
lucinations” and “conceptual disorganization”. Follow-up 
assessments were terminated in case of transition to psycho-
sis, or if no transition occurred after 5–7!years.
Outcome assessment
Study drop-out during follow-up was defined as the primary 
outcome variable and was assessed prospectively. CHR-P 
patients were considered as drop-out when no contact 
could be established for at least 1!year after several contact 
attempts had not been successful. Contact attempts included 
phone calls, letters, e-mails, text messages or contact with 
family members or general practitioners and other medical 
professionals, if release from medical confidentiality had 
been provided previously. CHR-P patients were also consid-
ered as having dropped out from our study when they explic-
itly refused to further participate in the study. In this case, 
drop-out reasons were assessed and documented on specific 
drop-out protocols. For those patients who dropped out, the 
drop-out date was defined as the date of their last visit.
To test whether study drop-out could be used as a proxy 
for service disengagement, we additionally assessed whether 
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patients dropping out of our study also disengaged with our 
clinical service. To this end, electronical medical records of 
a subset of our sample were inspected.
Statistical analyses
All statistical analyses were conducted using the R envi-
ronment for statistical computing [33]. Drop-out was the 
primary outcome measure. However, according to the FePsy 
study design, follow-up assessment could be ceased either 
due to drop-out or due to transition to psychosis. Drop-
out and transition were treated as competing events, since 
CHR-P patients could only experience one of the two event 
types over follow-up.
In a first step, we investigated rates of drop-out and transi-
tion to psychosis over the whole course of follow-up using 
cumulative incidence curves (CIC), which are the compet-
ing risks analogs of Kaplan–Meier survival curves [34, 35].
To discriminate between CHR-P patients with and with-
out drop-out, and to test sociodemographic and clinical pre-
dictors, we applied competing risks survival analysis. We, 
therefore, fitted a cause-specific Cox proportional hazard 
model where the competing event “transition to psychosis” 
was treated as a censored category. We previously checked 
that the proportionality-of-hazards assumption was met. 
Univariable models were fitted for each potential predictor. 
Predictor variables included sociodemographic variables 
(age, sex, relationship status, living situation, occupation, 
functioning, level of education) as well as clinical varia-
bles (Axis-I diagnoses, type of CHR-P status (any of APS, 
BLIPS or GRD vs. URC only), cannabis use, current intake 
of antidepressants, BRPS and SANS subscales and illness 
insight). We additionally used inclusion date (i.e., inclusion 
from 2000 to 2008 vs. inclusion from 2009 to 2017) as a 
binary predictor because of the previously described meth-
odological changes in study design in 2009. Ten patients 
had been treated with antipsychotics during the follow-up, 
which could have altered their natural disease course, and 
were, therefore, considered right-censored at the time when 
treatment with antipsychotics started. Five patients could 
no longer participate because they had moved too far away 
and were, therefore, considered right-censored at the time 
of relocation. For each univariable model, likelihood ratio p 
values were estimated. Testing was two-tailed at a 5% sig-
nificance level and missings were excluded pairwise.
To examine whether patients presented with increasing 
or decreasing symptoms immediately before drop-out, we 
assessed a potential change in symptoms over time. We, 
therefore, compared BPRS sub- and total scales of the last 
and second-last assessments and applied dependent sample 
t tests. For this analysis, we only included CHR-P patients 
with study drop-out and a maximum time di"erence of 
120!days between the last and second-last assessment.
Results
Sample characteristics
A total of 739 patients with suspected CHR-P were screened, 
of whom 310 were identified as having a CHR-P, 308 met 
criteria for FEP, and 121 were not at-risk for psychosis. Of 
the 310 CHR-P patients, 277 met our inclusion criteria. Of 
these, 200 provided written informed consent and thus were 
included in this study (see Table!1 for sociodemographic 
and clinical sample characteristics). The 77 patients who 
refused to participate did not di"er from the 200 included 
patients with regard to gender and years of education but 
they were significantly older  (MParticipants = 25.1! years; 
 MRefusers = 29.5!years).
Rate and!reasons of!drop-out
Within 5!years, 53 patients dropped out from the study 
and 43 transitioned to psychosis. An inspection of medical 
Table 1  Sociodemographic and clinical sample characteristics
N is the number of non-missing values. Values of continuous varia-
bles are stated as mean ± 1 standard deviation. All other variables are 
given in total numbers and percentages in parentheses
APS attenuated psychotic symptoms, BLIPS brief limited intermittent 
psychotic symptoms, GRD genetic risk and deterioration syndrome, 
URC unspecific risk category, BPRS Brief Psychiatric Rating Scale, 
SANS Scale for the Assessment of Negative Symptoms, GAF Global 
Assessment of Functioning
a Patients can meet criteria for more than one specific category













!URC only 40 (20.0%)
Antipsychotics  currentlyb 200 9 (4.5%)
Antidepressants currently 200 47 (23.5%)
Anxiolytics currently 200 25 (12.5%)
BRRS total score (mean ± SD) 189 39.28 ± 8.81
SANS total score (mean ± SD) 187 21.54 ± 16.09
GAF score (mean ± SD) 157 55.45 ± 10.69
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records revealed that only two patients with study drop-out 
still remained in our clinical service. The estimated cumu-
lative incidence curves for both drop-out and transition are 
displayed in Fig.!1. The risk of dropping out within 1, 2, 3, 
4, and 5!years of the follow-up was estimated as 0.13, 0.20, 
0.26, 0.33 and 0.36, respectively. The respective transition 
risk was estimated as 0.15, 0.18, 0.22, 0.24, and 0.28. The 
mean follow-up time of patients with later drop-out was 
1.55!years and 1.23!years of patients with a subsequent tran-
sition to psychosis.
Of those with drop-out, 41 patients (77.4%) explicitly 
requested to discontinue follow-up assessments. The identi-
fied reasons for refusal were: symptomatic improvement, 
and therefore no more need for service (6 patients, 14.6%), 
transition to another mental health service or psychothera-
pist (3 patients, 7.3%), lack of time and interest (4 patients, 
9.8%), being annoyed by requests for study participations (8 
patients, 19.5%) and no specific reason (16 patients, 39.0%). 
Information was missing for 4 patients (9.8%). Twelve out of 
53 patients (22.6%) could not be reached for at least 1!year 
after several attempts and were, therefore, considered as 
drop-out.
Baseline predictors of!study drop-out
Results of competing risks survival analysis are pre-
sented in Table!2. Univariate cause-specific hazard models 
revealed that patients with a late inclusion into the service 
(2009–2017) were significantly more likely to drop out than 
patients with an early inclusion (2000–2008). Furthermore, 
patients with a higher baseline score in the BPRS disor-
ganization scale were significantly more likely to drop out. 
Notably, no other baseline sociodemographic or clinical pre-
dictors significantly predicted study drop-out. Results of the 
cause-specific hazard models for transition to psychosis can 
be found in the supplementary material.
Change in!symptoms from!second-last to!last 
assessment in!patients with!study drop-out
Twenty-five patients were found to have a maximum time 
di"erence of 120!days between the second-last and last 
assessment before study drop-out, and thus were included in 
this analysis. When examining a potential change in symp-
toms, we observed that only BPRS-negative symptoms had 
significantly improved over time  (Msecond-last = 4.18 and 
SD = 1.55;  Mlast = 3.56 and SD = 1.16; p = 0.019). There 
were no significant differences from the second-last to 
last assessment in BPRS total score  (Msecond-last = 33.00 
and SD = 8.82;  Mlast = 30.90 and SD = 6.10; p = 0.097), 
BPRS positive symptoms  (Msecond-last = 4.52 and SD = 1.71; 
 Mlast = 4.08 and SD = 1.55; p = 0.156), BPRS activation 
 (Msecond-last = 3.40 and SD = 0.91;  Mlast = 3.42 and SD = 0.84; 
p = 0.918), BPRS a"ect  (Msecond-last = 4.90 and SD = 1.85; 
 Mlast = 4.56 and SD = 1.47; p = 0.356) and BPRS disorgani-
zation  (Msecond-last = 3.62 and SD = 1.09;  Mlast = 3.48 and 
SD = 0.92; p = 0.577). The results of the dependent sample 
t tests can be found in Fig.!2.
Discussion
The present study is one of the first to study rates, reasons 
and predictors of study drop-out and service disengagement 
in CHR-P patients. We found that 36% of CHR-P patients 
dropped out from the study within 5!years and almost all of 
them also disengaged from our clinical service after study 
drop-out. Hence, in this study drop-out can be used as proxy 
for service disengagement. We found that study drop-out 
and service disengagement during follow-up were signifi-
cantly associated with higher levels of baseline disorganized 
symptoms and with being included in the study after 2009. 
Moreover, we found that negative symptoms had significantly 
improved from the second-last to the last assessment before 
study drop-out, whereas positive symptoms had not changed.
The drop-out and disengagement rate of 36% after 5!years 
of follow-up in our study is rather low compared to previous 
studies, which reported drop-out rates of 36% after 2!years of 
follow-up [8] and 68% after 3!years [9]. Our low rate might 
be attributed to methodological di"erences regarding the 
operationalization of study drop-out. In our study, patients 



















Transition to psychosis Drop!out
Fig. 1  Estimated cumulative incidence curves for both study drop-out 
and transition, which show the estimated proportion of patients with a 
drop-out (blue) and transition to psychosis (red) on the y-axis for dif-
ferent lengths of follow-up on the x-axis
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Table 2  Competing Risks 
survival analysis for study 
drop-out
N is the number of non-missing values. Values of continuous variables are stated as mean ± 1 standard 
deviation. All other variables are given in total numbers and percentages in parentheses
HR hazard ratio, CI 95% confidence interval, Ref reference value, *p % 0.05, GAF Global Assessment of 
Functioning, SANS Scale for the Assessment of Negative Symptoms, BPRS Brief Psychiatric Rating Scale
N No drop-out Drop-out Test statistic
N = 147 N = 53 HR CI p value
Age 200 25.2 ± 7.1 24.8 ± 6.2 0.99 [0.95; 1.02] 0.479
Sex 200 0.376
!Women 43 (29.3%) 19 (35.8%) Ref.
!Men 104 (70.7%) 34 (64.2%) 0.78 [0.44; 1.36]
Inclusion date 200 0.010*
!2000–2008 63 (42.9%) 19 (35.8%) Ref.
!2009–2017 84 (57.1%) 34 (64.2%) 2.11 [1.18; 3.77]
Relationship status 168 0.270
!In a relationship 32 (25.0%) 14 (35.0%) Ref.
!Not in a relationship 96 (75.0%) 26 (65.0%) 0.69 [0.36; 1.33]
!Living situation 167 0.218
!Alone 52 (40.6%) 20 (51.3%) Ref.
!With partner or relatives 76 (59.4%) 19 (48.7%) 0.68 [0.36; 1.27]
Occupational status 168 0.838
!No occupation 42 (32.6%) 14 (35.9%) Ref.
!Working or studying 87 (67.4%) 25 (64.1%) 0.93 [0.49; 1.80]
Years of education 200 11.5 ± 2.7 12.3 ± 3.0 1.07 [0.98; 1.16] 0.115
Highest education 200 0.678
!Elementary/middle school 71 (48.3%) 27 (50.9%) Ref.
!Apprenticeship 30 (20.4%) 9 (17.0%) 0.71 [0.33; 1.51]
!High school 11 (7.5%) 5 (9.4%) 1.28 [0.49; 3.34]
!Qualification for university 28 (19.0%) 11 (20.8%) 1.07 [0.53; 2.16]
!Bachelor/Master’s degree 7 (4.8%) 1 (1.9%) 0.39 [0.05; 2.89]
Cannabis use 164 32 (25.6%) 14 (35.9%) 1.49 [0.77; 2.86] 0.235
Antidepressants currently 200 34 (23.1%) 13 (24.5%) 0.90 [0.48; 1.68] 0.735
Unspecific risk only 200 32 (21.8%) 8 (15.1%) 0.70 [0.33; 1.49] 0.359
Current a"ective disorder 161 44 (35.2%) 14 (38.9%) 1.12 [0.57; 2.18] 0.751
Current anxiety disorder 161 17 (13.6%) 9 (25.0%) 1.65 [0.78; 3.51] 0.189
GAF 157 55.7 ± 10.6 54.7 ± 11.0 0.98 [0.95; 1.01] 0.233
Illness insight 134 0.481
!Not present/questionable 24 (22.6%) 5 (17.9%) Ref.
!Present 82 (77.4%) 23 (82.1%) 1.41 [0.54; 3.73]
SANS
!Total score 187 21.6 ± 15.6 21.4 ± 17.6 1.00 [0.98; 1.02] 0.993
!A"ective flattening 185 4.9 ± 6.2 5.3 ± 6.1 1.01 [0.96; 1.06] 0.772
!Alogia 186 2.5 ± 3.7 2.9 ± 4.1 1.00 [0.94; 1.08] 0.920
!Avolition/apathy 187 5.4 ± 3.1 5.0 ± 3.5 1.00 [0.91; 1.09] 0.951
!Asociality/anhedonia 183 7.5 ± 5.3 7.0 ± 5.7 0.99 [0.94; 1.05] 0.703
!Inattention 170 2.0 ± 2.4 1.6 ± 2.0 0.97 [0.83; 1.13] 0.665
BPRS
!Total score 189 38.8 ± 8.6 40.8 ± 9.5 1.02 [0.99; 1.05] 0.177
!Positive symptoms 190 5.4 ± 2.0 5.7 ± 2.4 1.10 [0.96; 1.26] 0.171
!Negative symptoms 189 5.4 ± 2.7 5.8 ± 2.9 0.99 [0.89; 1.10] 0.884
!Activation 189 3.9 ± 1.7 3.6 ± 1.1 0.91 [0.73; 1.13] 0.371
!A"ect 188 6.7 ± 2.8 7.1 ± 3.0 1.05 [0.95; 1.15] 0.343
!Disorganization 189 3.8 ± 1.3 4.2 ± 1.5 1.21 [1.01; 1.45] 0.039*
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could be established for at least 1!year. However, clear and 
widely accepted definitions of study drop-out and service 
disengagement are lacking both for ARMS and FEP patients 
so far [11, 13]. Other studies have used lower [15, 16, 36, 
37], as well as higher thresholds [38, 39], analyzed di"erent 
follow-up durations [8, 9], or defined di"erent types of dis-
engagement [14]. Engagement and disengagement are often 
measured through attendance [11], as we did in our study. 
Yet, there are also studies describing service engagement 
and disengagement as multidimensional, multifaceted con-
structs comprising more than just service attendance [10, 11, 
40, 41]. A multidimensional understanding of service dis-
engagement as proposed by Tindall et!al. [41], for example, 
could have provided further useful insights. The authors sug-
gest understanding engagement as a process incorporating 
di"erent stages. In these, circumstances can push a person 
towards engagement (e.g., fear of relapse or a good relation-
ship with the case manager), or pull them from engagement 
(e.g., not wanting to open up, or a change in case manager).
Interestingly, we found a significant association between 
the study inclusion date and drop-out/service disengagement. 
CHR-P patients who were included between 2009 and 2017 
dropped out significantly more often than those included 
between 2000 and 2008. This might be due to changes in 
the study design applied in 2009. Specifically, whereas 
CHR-P patients with a low risk were followed-up three-
monthly in the first year when included before 2009, they 
were followed up monthly (i.e., treated equally as high risk 
patients) when included after 2009. Additionally, in 2011, 
we implemented an e-mail reminder system to facilitate the 
management of follow-up time points for care givers. Our 
case managers set their schedule for follow-up visits accord-
ing to weekly reminder e-mails, which might have resulted in 
patients being contacted more often and especially in shorter 
intervals. Moreover, starting in 2011, patients were asked to 
additionally participate in two further multicenter studies on 
the early detection and treatment of psychosis [31, 32, 42]. 
We, therefore, speculate that contacting patients too often 
or burdening them with too many assessments might lead to 
unintended e"ects, such as patients being annoyed by it and 
therefore disengaging from the clinical service. In line with 
this, some patients even declared being annoyed by requests 
for study participations when asked about a specific reason 
for service disengagement.
Negative Symptoms Positive Symptoms Total score
Activation Affect Disorganization
!120 !90 !60 !30 0 !120 !90 !60 !30 0 !120 !90 !60 !30 0

































Fig. 2  Change in symptoms from second-last to last assessment in patients with study drop-out. Fine gray lines represent individual trajectories 
and thick blue lines represent averaged trajectories for each of the six psychopathological symptom dimensions
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Although lack of insight has been associated with service 
disengagement in FEP patients, we could not find any such 
association in CHR-P patients. One possible explanation 
is that illness insight in CHR-P patients is relatively intact 
compared to FEP patients [43]. Accordingly, in our sample 
only 21.6% of CHR-P patients were considered to have lack-
ing or questionable insight according to the BIP [24]. There-
fore, it seems possible that insight does not play a major role 
in service disengagement in the at-risk population.
Contrary to our hypotheses, we could not demonstrate 
any association between cannabis consumption and study 
drop-out/service disengagement. Substance abuse and 
dependence are among the most robust predictors of disen-
gagement in FEP patients, with cannabis use in particular 
increasing risk of disengagement [13]. Notably, although 
not significant, the association between cannabis use and 
service disengagement in our study was in the same direc-
tion as in studies with FEP patients. It might be possible that 
cannabis consumption only leads to service disengagement 
in combination with more severe symptoms in later stages of 
psychotic disorders [13]. Alternatively, our non-significant 
finding might also be the result of low statistical power, as 
only 14 of 53 patients with service disengagement reported 
cannabis use at baseline. Further studies addressing the asso-
ciation between cannabis use and disengagement in larger 
CHR-P patient samples are warranted.
Regarding baseline clinical and sociodemographic vari-
ables, there were almost no associations with study drop-out/
service disengagement. These results are largely consistent 
with previous studies investigating study drop-out/service 
disengagement in CHR-P patients [8, 9, 12]. Regarding the 
lacking influence of negative symptoms, our results are con-
sistent with those of a large study by Stowkowy et!al. [8] 
in 764 CHR-P patients, although another study did report 
an association with service disengagement [9]. On the 
other hand, our finding that higher baseline disorganized 
symptoms significantly elevated disengagement risk was 
rather unexpected. The only available study that explic-
itly reported findings regarding disorganized symptoms in 
CHR-P patients [8] could not demonstrate an association 
with service disengagement. Our contrasting finding may be 
attributed to the use of di"erent instruments assessing disor-
ganized symptom severity and di"erent methods of dealing 
with patients with a subsequent transition in the statistical 
analysis.
For the first time, we investigated whether a change in 
symptoms had occurred immediately before study drop-out. 
While positive symptoms and all other subscales from the 
BPRS had not significantly worsened, negative symptoms 
had significantly improved between the second-last and last 
assessment. Thus, it appears unlikely that patients disen-
gaged from the service because of increased suspiciousness 
or a transition to psychosis. Our results rather suggest that 
an improvement of negative symptoms and thus better social 
functioning might lower the need for treatment, and thereby 
increases the likelihood of dropping out. Hence, the duration 
of follow-up might have been too long for patients expe-
riencing significant symptomatic improvement during the 
follow-up, which might have artificially increased the drop-
out rate at later follow-up time points. However, it should be 
emphasized that in our study, positive symptoms remained 
relatively stable from the second-last to last appointment. 
This indicates that at least some patients might still su"er 
from subthreshold psychotic symptoms at the time of dis-
engagement and still be at-risk for psychosis. This would 
be in line with our recent ultra-long-term follow-up study, 
which showed that some patients still transit to psychosis 
after many years [44]. Hence, it might be di#cult to strike 
the right balance between capturing late transitions and 
not imposing a burden on patients. It might, therefore, be 
prudent to extend follow-up visit intervals with increasing 
follow-up duration, as has already been done in this study, 
or to flexibly adapt the frequency and length of follow-ups 
according to the symptom severity.
Strengths and!limitations
Strengths of this study were the longitudinal design and 
the application of competing risk survival models, which 
allowed us to take transition to psychosis and the time to 
event into account. Furthermore, we evaluated a large num-
ber of predictor variables, including cannabis use and illness 
insight, regarding their association with service disengage-
ment in this specific patient group for the first time. Addi-
tionally, to the best of our knowledge, this study is the first to 
investigate changes in symptoms immediately before study 
drop-out.
A limitation of this study is that we did not assess fur-
ther potential predictors previously associated with service 
disengagement in FEP patients such as forensic history [13, 
14, 45] or therapeutic alliance and quality of the relationship 
with the case manager, which have earlier been described as 
vital engagement reasons [11, 41].
Conclusion
In conclusion, sociodemographic and clinical baseline vari-
ables in great part did not predict study drop-out/service 
disengagement during follow-up in CHR-P patients. How-
ever, we observed that patients with a later inclusion into our 
project were at significantly greater risk for study drop-out/
service disengagement, which might have occurred because 
the patients were burdened with increased assessments 
during the later time period. Hence, our study provides a 
cautionary note on high frequency follow-up assessments 
in this specific patient group. Larger-scale studies using 
Social Psychiatry and Psychiatric Epidemiology 
1 3
multidimensional assessments to evaluate predictors on 
multiple levels (e.g., clinical, sociodemographic, therapist) 
would help to further elucidate study drop-out and service 
disengagement in CHR-P patients.
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A B S T R A C T
Background: Few studies have followed up patients with a clinical high risk (CHR) for psychosis for more
than 2–3 years. We aimed to investigate the rates and baseline predictors for remission from CHR and
transition to psychosis over a follow-up period of up to 16 years. Additionally, we examined the clinical
and functional long-term outcome of CHR patients who did not transition.
Methods: We analyzed the long-term course of CHR patients that had been included in the longitudinal
studies “Früherkennung von Psychosen” (FePsy) or “Bruderholz” (BHS). Those patients who had not
transitioned to psychosis during the initial follow-up periods (2/5 years), were invited for additional
follow-ups.
Results: Originally, 255 CHR patients had been included. Of these, 47 had transitioned to psychosis during
the initial follow-ups. Thus, 208 were contacted for the long-term follow-up, of which 72 (34.6%)
participated. From the original sample of 255, 26%, 31%, 35%, and 38% were estimated to have transitioned
after 3, 5, 10, and 16 years, respectively, and 51% had remitted from their high risk status at the latest
follow-up. Better psychosocial functioning at baseline was associated with a higher rate of remission. Of
the 72 CHR patients re-assessed at long-term follow-up, 60 had not transitioned, but only 28% of those
were fully recovered clinically and functionally.
Conclusions: Our study shows the need for follow-ups and clinical attention longer than the usual 2–3
years as there are several CHR patients with later transitions and only a minority of CHR those without
transition fully recovers.
© 2019 Elsevier Masson SAS. All rights reserved.
1. Introduction
The majority of patients with schizophrenic psychoses experi-
ence a prodromal phase with !rst signs and symptoms, beginning
on average 3–4 years before the onset of frank psychosis [1,2].
Based on this evidence, the concept of the clinical high risk (CHR)
state for psychosis was developed approximately two decades ago,
including speci!ed criteria such as the presence of attenuated
psychotic symptoms, short limited psychotic symptoms or genetic
risk and functional decline [3].
A large body of research has since been conducted to establish
and optimize early detection of the early stages of the disorder and
to predict transition to frank psychosis. Current meta-analytical
evidence indicates that about 20% of CHR patients develop frank
psychosis [4] and about 35% remit from their CHR state [5] within
two years after initial identi!cation. The speed of psychosis
progression tends to plateau from the third year on, reaching a
cumulative transition risk of about 35% after 10 years [6].
Therefore, most previous studies have focused on the !rst 2–3
years after initial identi!cation [7–9] and there is only little
evidence on the long-term outcome of CHR patients [10–15].
Although CHR patients without later transition (CHR-NT
patients) make up the majority of CHR samples [4,9], little is
known about their clinical and functional long-term outcome. So
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far, there are only very few studies evaluating non-psychotic
clinical and functional outcome of CHR-NT patients with follow-up
durations of more than 2 years [10–12,15]. These studies indicate
that even CHR patients without transition to frank psychosis
experience (subclinical) psychotic symptoms, non-psychotic dis-
orders and psychosocial impairments in the long-term [10–12,15],
although most of the comorbid disorders seem to be already
present at baseline [16,17].
However, the existing long-term studies on CHR-NT patients
have several methodological limitations. Functional outcome was
frequently assessed by the GAF in which the level of functioning is
rated based on psychosocial functioning or clinical symptoms,
whichever area is more impaired, leading to a con"ation of both.
Most studies reported rates of remission from the CHR state only
for certain points in time. Furthermore, a risk estimate that takes
into account the “competing” risk of transition and the usually
considerable proportion of drop-outs was rarely provided.
Little is known about how many CHR patients transition to
frank psychosis and how many remit from their clinical high risk
state in the long term. Furthermore, limited information is
available on the clinical and functional outcome of those who
do not transition, e.g., regarding subclinical psychotic symptoms,
non-psychotic clinical symptoms and diagnoses such as depres-
sion and anxiety, psychosocial functioning and overall recovery.
Insight into the long-term outcome of CHR-NT patients could
inform clinical service planning and future research on the CHR
state.
In this study, we therefore thoroughly investigated the ultra-
long-term course (up to 16 years) of CHR patients, evaluating
transitions to psychosis over the whole follow-up period including
late transitions. Furthermore, we assessed the clinical and
functional outcome of those without transition, i.e., the rates of
remission from the CHR state, clinical symptoms and axis I
diagnoses, functional outcome, and the prevalence of full clinical
and functional recovery. Moreover, we aimed to investigate
predictors of clinical and functional outcome in CHR-NT patients
at long-term follow-up as to the best of our knowledge this has not
previously been investigated. Based on a systematic review [15],
we expected that most CHR-NT patients do not recover function-
ally and clinically during several years of follow-up.
2. Methods
2.1. Participants and procedure
Patients with a clinical high risk (CHR) for psychosis were
recruited via the prospective Früherkennung von Psychosen (FePsy)
study [18,19] and the Bruderholz study (BHS) [20]. Both were
prospective clinical studies of all consecutive referrals from de!ned
catchment areas to the specialized early detection centers of the
counties of Basel city (FePsy) and Basel countryside (BHS). Patients
received treatment according to needs, case-management, and
supportive psychotherapy during the follow-up. Antipsychotic
treatment was only initiated after transition to psychosis had
occurred. Further details regarding the characteristics of the studies
can be found in Table 1 and in previous publications [18–20]. Both
studies were approved by the Ethics Committee northwest/central
Switzerland (EKNZ) and all participants provided written informed
consent. If subjects were under age 18, additional written informed
consent was obtained from their parents.
All CHR patients who did not transition to frank psychosis
during the respective initial follow-up periods, including patients
who dropped out and did not complete all planned follow-up
assessments, were regarded as patients without initial transition
(CHR-NT), and were asked to take part in the long-term follow-up
assessment of the current study (see Supplementary Materials
page 1 for detailed information on the very thorough contact
procedure).
Patients who refused to participate in the extensive long-term




Baseline parameters and measures are reported in Table 1.
2.2.2. Follow-up assessments
CHR status was re-evaluated at each follow-up visit using the
positive symptom items of the Brief Psychiatric Rating Scale –
Expanded (BPRS-E) [22,23] in the FePsy study and the Structured
Interview for Prodromal Symptoms/Scale of Prodromal Symptoms
(SIPS/SOPS) [24,25] in the Bruderholz study.
Remission from CHR. Remission from CHR was de!ned as the
absence of attenuated psychotic symptoms (APS) or brief limited
intermittent psychotic symptoms (BLIPS), i.e., sub-threshold
severity scores on all positive symptom items of the BPRS-E
(FePsy) or SOPS (BHS) for at least 12 consecutive months preceding
the latest follow-up assessment. Thus, in the FePsy study, the
four BPRS-E symptoms relevant for this assessment had to be
constantly under the following thresholds: suspiciousness ! 2,
hallucinations ! 1, unusual thought content ! 2, and formal
thought disorder ! 2. In the Bruderholz study, the !ve positive
psychotic symptom items of the SOPS had to be constantly ! 2.
Both sets of criteria are similar to those used by Schlosser et al. [26].
The date of remission was de!ned as the date at which the APS/
BLIPS-free period lasting at least 12 months started. In those CHR-
NT patients who participated in the long-term follow-up assess-
ment, the date of remission was determined retrospectively for the
whole follow-up period including the initial follow-up period. In
those patients who did not take part in the long-term assessment,
remission was evaluated by using all BPRS-E/SOPS positive
symptom ratings of the initial follow-up period.
Transition to psychosis according to the criteria by Yung and
colleagues [3] was also evaluated not only at each follow-up
assessment but also retrospectively for the entire follow-up period
by considering all available information, including medical
records.
Non-remission from CHR. In case neither remission from CHR
nor transition to psychosis occurred, patients were considered
non-remitted at the time point they were last seen. This was the
date of the long-term follow-up visit for patients participating in
the long-term follow-up, whereas for patients not participating
in the long-term follow-up this was the last visit in the initial
follow-up.
Psychosocial functioning in CHR-NT patients at long-term
follow-up, referring to the preceding 4 weeks, was evaluated by
the Personal and Social Performance scale (PSP) [27] which is
based on the Social and Occupational Functioning Scale (SOFAS)
[28] and has been validated in many languages, including German
[29]. Functioning is assessed in four domains, i.e., occupational
functioning, interpersonal relationships, self-care, and presence of
disturbing/aggressive behavior. Overall functioning is expressed in
a global score. For the current study a global score of ! 70 was
de!ned as functional impairment since scores above 70 indicate no
or mild dysfunction [27].
The Structured Clinical Interview for DSM-IV Axis I Disorders
(SCID-I) [30,31] was used to assess current axis I diagnoses in CHR-
NT patients at long-term follow-up.
Full clinical and functional recovery at long-term follow-up was
de!ned as meeting all of the following criteria: no transition to
frank psychosis, remission from CHR, good functional outcome
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(PSP global score > 70), and the absence of any current axis I
disorder in accordance with Rutigliano et al. [32].
2.3. Statistical analyses
Statistical analyses were conducted using the R environment for
statistical computing [33]. Analyses were conducted in two
different samples: 1) the initial baseline sample of all CHR patients
and 2) the sample of CHR patients who participated in the long-
term follow-up assessment of the current study and had not
transitioned to frank psychosis during the whole follow-up period.
To test the representativity of the second sample, we compared
those who participated in the long-term follow-up assessment
with those who did not regarding various socio-demographic and
clinical characteristics – both at baseline and at their last visit of
the initial follow-up period.
In the !rst sample we investigated of CHR remission and
transition rates over the whole follow-up period using cumulative
incidence curves (CIC) which are the competing risks analogs of
Kaplan-Meier survival curves [34]. We used proportional cause-
speci!c hazards models to investigate baseline predictors for
remission from CHR and transition to psychosis, i.e., age and
gender, positive symptoms, negative symptoms, psychosocial
functioning, and current cannabis use.
In the second sample we conducted 1) logistic and 2) multiple
regression analyses to examine the predictive value of the
aforementioned baseline socio-demographic and clinical variables
regarding 1) remission from CHR and 2) psychosocial functioning
at the long-term follow-up assessment. For each predictor variable,
a separate model was !tted that additionally included study (FePsy
vs. BHS) as covariate.
3. Results
3.1. Initial baseline sample (all CHR patients)
The initial baseline sample consisted of 255 CHR patients. The
average follow-up duration (mean " SD; range) of the whole
Table 1
Characteristics of the FePsy and Bruderholz studies.
FePsy study Bruderholz study
Inclusion period: # 3/01/2000 – 07/31/2014 # 2003 – 2006
Initial follow-up: # up to 5-7 years
# monthly (1st year), 3-monthly (2nd and 3rd year), and annually
thereafter
# up to 2 years
# 3-monthly to annually
CHR criteria Risk criteria according to BSIP:
# Attenuated psychotic symptoms (APS)
# Brief limited intermittent psychotic symptoms (BLIPS)
# Genetic risk and combination of certain prodromal symptoms/risk
factors, including deterioration in functioning (GRD)
UHR criteria according to SIPS/SOPS:
# Attenuated psychotic symptoms (APS)
# Brief limited intermittent psychotic symptoms (BLIPS)
# Genetic risk and deterioration syndrome (GRD)
# Unspeci!c risk category (URC), i.e., combination of a minimum
number of certain prede!ned prodromal symptoms/risk factors
Basic symptom criterion:
# At least one “predictive basic symptom” [1] with a SPI-A score $ 3
Exclusion criteria # age < 18 years
# IQ < 70
# previous psychotic episode (with transition acc. to Yung et al. [3]
# antipsychotic treatment for >3 weeks (lifetime) and/or total amount
of
# $ 2500 mg chlorpromazine equivalents
# (pre-)psychotic symptoms only within a clearly diagnosed affective
psychosis or borderline personality disorder
# (pre-)psychotic symptoms clearly due to organic reasons or
substance abuse only
# insuf!cient knowledge of German
# age < 14 years
# IQ < 70
# previous psychotic episode
# traumatic brain injury, epilepsy or other known neurological
disorder
# other signi!cant medical condition considered to affect cognitive
performance and self-perception
Baseline measures at initial study intake




# BPRS-E [2] # PANSS
Psychosocial
functioning
# GAF # GAF
Axis I diagnoses # SCID-I for DSM-IV # SCID-I for DSM-IV
Cannabis use # Basel Interview for Psychosis (BIP) # Bruderholz Demography Questionnaire (BDQ)
Transition criteria # acc. to Yung et al [3]; BPRS-E # acc. to Yung et al [3]; SOPS
Note: FePsy study = Früherkennung von Psychosen (Basel early detection of psychosis) study; Bruderholz study = Basel countryside early detection of psychosis study;
CHR = Clinical high risk for psychosis; SIPS = Structured Interview for Prodromal Symptoms / SOPS = Scale of Prodromal Symptoms (McGlashan et al, 2001([24])); BSIP = Basel
Screening Instrument for Psychosis (Riecher-Rössler et al [42]; Peralta et al (43)); SIPS = Structured Interview for Prodromal Symptoms; SOPS = Scale of Prodromal Symptoms;
SPI-A = Schizophrenia Proneness Instrument, Adult version (Schultze-Lutter et al (44)); PANSS = Positive and Negative Syndrome Scale (Kay, Fiszbein, & Opler (45)); BPRS-
E = Brief Psychiatric Rating Scale – Expanded (Ventura et al (23)); GAF = Global Assessment of Functioning scale of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV; American Psychiatric Association (28)); SCID-I = Structured Clinical Interview for DSM-IV Axis I Disorders (First & Gibbon [30]; Wittchen, Gruschwitz & Zaudig
(31)); BIP (Riecher-Rössler et al (46)).
aAccording to Klosterkötter et al [47]: thought interference, thought perseveration, thought pressure, thought blockages, disturbances of receptive language, decreased ability
to discriminate between ideas and perception, fantasy and true memory, unstable ideas of reference, derealization, visual and acoustic perception disturbances.
bPositive and negative symptom subscales according to Shafer et al ([21]).
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initial sample was 3.9 " 4.1 (range: 0–16.6), of those with later
transition 2 " 2.5 (0.01–11.21), and of those without transition
8.2 " 4.4 (0.1–16.6) years, respectively.
3.2. Ultra-long-term follow-up sample of CHR-NT patients
Forty-seven CHR patients of the initial baseline sample had
been detected to have had transitioned to frank psychosis during
initial follow-up. Thus, 208 CHR patients without initially
detected transition (CHR-NT) were contacted and invited to
participate in the ultra-long-term follow-up assessment. Of these,
72 (34.6%) did participate (71 face-to-face interviews, 1 telephone
interview), 28 (13.5%) refused to take part, and 108 (51.9%) could
not be reached. For two further patients only medical records were
available, including information on transition status. Twelve
patients participating in the long-term follow-up assessment
turned out to have had transitioned in the meantime. Therefore,
the long-term sample of CHR-NT patients consisted of 60
participants. Further details on the study sample can be found
in Fig. 1 and Table 2.
There were no signi!cant group differences between CHR
patients who participated in the long-term follow-up assessment
(n = 72) and those who did not (n = 183) regarding various
sociodemographic and clinical variables (all p-values > 0.05; data
available upon request), indicating a high representativity of the
long-term follow-up sample.
3.3. Clinical outcome of the total initial CHR sample (n = 255)
3.3.1. Rates of transition to psychosis
Overall, 60 patients had transitioned to frank psychosis. At
2-, 3-, 4-, and 5-year follow-up the estimated transition rates
were 18.7%, 23.1%, 25.9%, and 30.8%, respectively. Ten and 15 years
after baseline the rates were 34.9% and 38.2%, respectively
(for the proportions of transitions for each year see Fig. 2 and
Table S2).
Fig. 1. Flow diagram of the study population.
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3.3.2. Rates of remission from CHR
The proportion of patients with a remission from CHR within
the !rst 2, 3, 4, and 5 years of follow-up was estimated with
the cumulative incidence curve as 23.7%, 32.8%, 36.4%, and
37.4%, respectively. Ten years after initial baseline an estimated
proportion of 51.4% had remitted, with no further remissions after
that time point (for the rates of remissions at each year after initial
baseline, see Fig. 2 and Table S2).
3.3.3. Baseline predictors of remission from CHR
In the overall CHR sample, better psychosocial functioning at
baseline was associated with a higher likelihood of remission from
CHR during follow-up (p = 0.003). Age, sex, positive and negative
symptoms as well as cannabis use were not signi!cantly associated
with remission (see Table 3).
3.4. Clinical and functional outcome of the CHR-NT long-term follow-
up sample (n = 60)
The mean follow-up duration of the CHR-NT long-term follow-
up sample was 8.2 " 4.4 (range: 0.1–16.6) years. The average
follow-up duration was 7.1 " 4.3 (1.2–16.6) years of those with later
remission from the CHR state and 2.5 " 3.2 (0–15.1) years of those
who neither remitted nor transitioned, respectively.
Of the 60 CHR-NT patients of the long-term follow-up sample,
51 (85%) had remitted from their high risk status (CHR), 39 (65%)
had not any axis I diagnosis, 31 (51.7%) showed good psychosocial
functioning. All in all, only 17 (28.3%) had fully recovered clinically
and functionally. For further characteristics of the long-term
follow-up sample see Table 2 and Fig. 3.
3.4.1. Baseline predictors of remission from CHR and psychosocial
functioning at long-term follow-up (n = 60)
There were no signi!cant associations between any of the
baseline variables and remission from CHR at long-term follow-up
(all p-values > 0.05; see Table S3). However, higher age (p = 0.06)
and less negative symptoms (p = 0.09) at baseline were associated
with better psychosocial functioning at long-term follow-up at a
trend level (see Table S4).
Table 2
Socio-demographic and clinical characteristics of the CHR-NT patients of the long-term follow-up sample (n = 60) at baseline and long-term follow-up.
FePsy study (n = 40) Bruderholz study (n = 20) Total sample (n = 60)
M (SD; range) n (%) M (SD; range) n (%) M (SD; range) n (%)
Baseline
Age, years 26 (8.7; 18.2–56.8) 20.2 (5.7; 14.4–35.6) 24.1 (8.2; 14.4–56.8)
Gender, male 26 (65) 15 (75) 41 (68.3)
Education, years 12.4 (3; 8–19) 14.7 (3.3; 9–23) 13.1 (3.3; 8–23)
Positive symptoms
(BPRS-E/PANSS)
5.1 (2.2; 3–13) 5.5 (1.5; 3–8) 5.2 (2; 3–13)
Negative symptoms
(BPRS-E/PANSS)
5.7 (3; 3–14) 3.9 (1.6; 3–7) 5.3 (2.8; 3–14)
Psychosocial functioning (GAF) 58.8 (10.2; 42–90) 43.8 (12.6; 0–58) 53.6 (13.1; 0–90)
Current cannabis use (BIP), yes 7 (17.5) 1 (5) 8 (13.3)
Long-term follow-up
Age at follow-up, years 34 (11.4; 21.3–72.4) 31.1 (6.2; 24.1–48.8) 33 (10; 21.3–72.4)
CHR state (BPRS- E/PANSS)
Remission 33 (82.5) 18 (90) 51 (85)
Non-remission 7 (17.5) 2 (10) 9 (15)
Psychosocial functioning (PSP) 72 (10.1; 48–90) 73 (8.1; 58-87) 72.3 (9.4; 48–90)
Functional impairment, yesa 18 (45) 11 (55) 29 (48.3)
Any axis I diagnosis (SCID-I) 14 (35) 7 (35) 21 (35)
Mood disorder 2 (5) 5 (25) 7 (11.7)
Anxiety disorder 6 (15) 3 (15) 9 (15)
Substance use disorder 7 (17.5) 0 (0) 7 (11.7)
Full clinical and functional recoveryb 11 (27.5) 6 (30) 17 (28.3)
Time to remission from CHR [years] 1.6 (2.1; 0–10) 3.9 (4; 0–9.7) 2.4 (3.1; 0–10)
Note: CHR = Clinical high risk for psychosis; GAF = Global Assessment of Functioning scale of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; American
Psychiatric Association, [28]); BPRS-E = Brief Psychiatric Rating Scale – Expanded (Ventura et al. [23]); PANSS = Positive and Negative Syndrome Scale (Kay, Fiszbein, & Opler,
[45]); PSP = Personal and Social Performance Scale; GAF = Global Assessment of Functioning scale of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV;
American Psychiatric Association [28],); SCID-I = Structured Clinical Interview for DSM-IV Axis I Disorders (First & Gibbon, [30]; Wittchen, Gruschwitz & Zaudig, [31]); BIP
(Riecher-Rössler et al [46]).
a Personal and Social Performance Scale (PSP) total score ! 70.
b Remission from CHR and absence of functional impairment and no axis I disorder.
Fig. 2. Cumulative incidence curves.
Note: Estimated risks of remission from CHR and transition to frank psychosis over
the whole follow-up period. Numbers at risk indicate CHR patients who are still in
follow-up at this time point and neither remitted from their CHR nor transitioned.
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4. Discussion
We evaluated rates of transition and remission from the clinical
high risk state and their predictors in a large sample of CHR
patients over a follow-up period of up to 16 years. At the latest
follow-up time, an estimated 38% of the overall sample of 255
patients had transitioned to frank psychosis, 51% had remitted
from their CHR state, and 11% continued to experience subclinical
psychotic symptoms. A higher level of psychosocial functioning at
baseline was associated with a higher likelihood of remission from
the CHR state during the follow-up.
Of the 60 CHR patients who participated in our direct, personal
long-term follow-up assessments (i.e., at an average of 8 years after
baseline) and had not transitioned to psychosis, 85% had remitted
from their CHR state, 35% presented with at least one axis I
diagnosis (apart from the CHR state), 48% showed poor functional
outcome, and overall, only 28% had fully recovered clinically and
functionally. This suggests that the majority of CHR-NT patients
continue to experience clinical symptoms or functional impair-
ments, even many years after initial identi!cation. In this sample of
CHR-NT patients, higher age and less negative symptoms at
baseline were associated, at a trend level of signi!cance, with
better functional outcome at long-term follow-up.
4.1. Transition to psychosis
The present study estimated rates of transition for up to 16
years after initial referral, which – to our knowledge - is the longest
time period that has ever been reported. Overall, we estimated that
26% of CHR patients had developed frank psychosis after 3 years,
31% after 5 years, 35% after 10 years, and 38% after 16 years. Our
estimated transition rates in the !rst 4 years of the follow-up are
very similar to those reported in the most recent meta-analyses
[4,9]. As expected [4], most transitions occurred during the !rst
2–3 years of follow-up. However, several of our CHR patients had
experienced a “late transition” 4 or more years after initial
identi!cation.
So far, only very few studies have estimated cumulative
transitions rates for periods longer than 4 years [35,36]. In line
with our results, the study by Nelson et al [35] on 416 CHR patients
revealed cumulative transition rates of 28% and 35% after 4 and
10 years, respectively. In contrast, the study by Fusar-Poli et al [36]
on 509 CHR patients detected only few transitions after more than
4 years. However, they might have missed some late transitions as
their follow-up was limited to 10 years and they had a relatively
high rate of drop-outs.
The multiple late transitions revealed in our study and that of
Nelson et al [35] support the importance of follow-up durations
longer than three years. This is not only important to estimate the
true rates of transitions but also to evaluate the outcome of CHR
patients without transition to psychosis. The fact that there is quite
a number of late transitions also challenges many studies on risk
prediction, as most prediction models were developed based on
samples with short follow-up durations and can therefore only
make accurate predictions regarding the short term.
4.2. Remission from CHR
In the whole sample of CHR patients, including those who
transitioned, we estimated that 24% of CHR patients had remitted
Table 3
Baseline predictors of remission from CHR in the whole sample (n = 255).
Outcome
(Competing Event)
Variable Hazard Ratio Con!dence Interval p-value
Remission
(Transition)
Age 1 0.97–1.03 .83
Sex 0.99 0.62–1.56 .95
Positive symptoms 1.04 0.93–1.16 .49
Negative symptoms 0.96 0.88–1.05 .37
Psychosocial 1.04 1.01–1.06 .003**
Cannabis use 0.76 0.4–1.4 .39
*p ! .05.
** p ! .01.
Fig. 3. Clinical and functional outcome of CHR patients without transition to frank psychosis at ultra-long-term follow-up (n = 60).
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from their CHR state after 2 years, 32% after 3 years, 36% after
5 years, and 50% after 10 and 16 years, indicating that a
considerable number of CHR patients experience subclinical
psychotic symptoms even many years after initial identi!cation.
The only other study that has estimated cumulative remission
rates using competing risk survival analysis estimated 36%
remissions after two years [26]. Our results are also similar to
those of the meta-analysis of Simon et al. [5], which found a
remission rate of 35% after two years.
Of the CHR patients without transition that participated in our
direct long-term follow-up assessments 85% had remitted from
their CHR state. This is about 10% higher than in other studies
[5,10,11,37] which might be explained by the shorter average
follow-up durations of most of these studies compared to the on
average 8 years of follow-up in our sample.
Persistence of attenuated psychotic symptoms might indicate
an ongoing risk of transition to psychosis [38]. Recurrent
symptoms might also point towards a moderate disposition to
react to stress with subclinical psychotic symptomatology, but not
full psychosis due to, e.g., comparably low vulnerability and/or
good protective factors. Subclinical psychotic symptoms might also
indicate other diagnoses such as affective disorder, posttraumatic
stress disorder and borderline personality disorder.
4.3. Baseline predictors for remission from CHR
In the whole sample of CHR patients we found better
psychosocial functioning at baseline to be associated with a
higher remission rate. Not predictive were age, sex, positive
symptoms, negative symptoms, or cannabis use. A similar study of
Schlosser et al [26] found not only baseline psychosocial
functioning but also lower levels of negative symptoms to increase
the likelihood of remission. This discrepancy might be due to the
large difference in the follow-duration (up to 2 vs. 16 years) and
different measures of negative symptoms (i.e., SOPS vs. BPRS/
PANSS).
Poor psychosocial functioning is closely associated with
(emerging) psychosis and might be a more stable marker for
vulnerability to psychosis, i.e., non-remission from CHR, than
positive symptoms at baseline [39]. A subgroup of CHR patients
might not be predisposed to psychosis but might suffer from non-
psychotic disorders associated with decreased psychosocial
functioning and subclinical psychotic symptoms. CHR patients
with better psychosocial functioning at baseline might have a
higher resilience, including more internal and external resources
such as a good social network and support, and a stable school or
work environment. Those protective factors might contribute to
their remission from CHR.
If only the CHR-NT patients that participated in our direct long-
term follow-up assessments were considered, no signi!cant
associations between baseline predictors and remission from
CHR were found. This is in line with a study of Ziermans et al [40].
However thismight also be due to a lack of statistical power as only
few patients had not remitted from their CHR state (n = 9).
4.4. Clinical and functional ultra-long-term outcome of CHR-NT
patients
The relatively high proportion of CHR patients without
transition to psychosis diagnosed with clinical axis I diagnoses
and/or showing poor psychosocial functioning at long-term
follow-up is consistent with our recent review [15]. It suggests
that most patients still require clinical attention and should be
further examined. Despite the relatively large proportions of CHR-
NT patients presenting with non-psychotic disorders at long-term
follow-up, recent studies have shown that the clinical high risk
state for psychosis is not predictive for non-psychotic diagnoses
[17,41]. The large number of comorbidities in CHR-P patients could
at least partially be due to clinicians using other diagnosis as a
substitute for a CHR diagnosis as the latter is not yet included in the
DSM or ICD.
4.5. Limitations
We included patients from two different studies with slightly
different study designs. While the FePsy study evaluated CHR
patients aged 18 years or older, the Bruderholz study also
included adolescents who made up almost half of its sample.
Furthermore, the FePsy study used the BSIP for assessing CHR
criteria, whereas the Bruderholz study used the SIPS. In addition,
the initial follow-up duration was longer in the FePsy study (5–7
years) than in the Bruderholz study (2 years). Moreover, positive
and negative symptoms were assessed with the BPRS-E in the
FePsy study and the PANSS in the Bruderholz study. The small
number of non-remitted patients in the CHR-NT sample possibly
limits the statistical power of the analyses of predictors of
remission from CHR. Nevertheless, our study is one of the !rst to
extensively evaluate outcome of CHR patients over such a long
follow-up duration, using an advanced methodological ap-
proach to estimate remission and transition rates for a large
sample.
4.6. Conclusions
By investigating a relatively large sample of CHR patients over
a very long follow-up duration of up to 16 years, we could
demonstrate that several patients still transition to psychosis after
the usual time period assessed in most previous studies. We also
found that only a minority of CHR-NT patients had fully
functionally and clinically recovered at long-term follow-up. So
far, we have obviously underestimated the rate of late transitions
as well as the long-term prevalence of clinical symptoms and
functional impairments in CHR patients without transition. One
implication of our study is that existing prediction models, which
are mostly based on samples with short follow-up duration, can
predict transition to psychosis only at short-term. Our study
reinforces the need for longer follow-ups of patients at clinical high
risk for psychosis to provide adequate clinical care and inform
future research.
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A B S T R A C T
Background and objectives: Individualized Metacognitive Training (MCT+) is a manualized intervention de-
signed to improve delusional severity by reducing delusion-associated cognitive biases such as jumping-to-
conclusions. Increased interest in personalized medicine stipulates the identi#cation of patients who are more
likely to bene#t from specialized interventions. The present study aimed to explore baseline moderators of
MCT+ e!cacy on delusions and overall positive symptoms in psychosis.
Methods: We analyzed data from a randomized rater-blind controlled trial, in which 92 patients with psychotic
disorders and current or past delusions were randomly assigned to either MCT+ or CogPack®, a cognitive
remediation software. Baseline moderator variables consisted of jumping-to-conclusions, cognitive insight,
quality of life, self-esteem, selective attention, and patients’ attitudes towards their symptoms. Linear mixed-
e"ects models were applied to investigate speci#c moderators of MCT+ e!cacy.
Results: In MCT+ relative to CogPack, presence of a jumping-to-conclusions bias, a lowered decision threshold,
and low self-esteem were associated with larger improvements in delusional severity and/or overall positive
symptoms over time. Subjective reasoning style and insight, as well as subjective attitudes towards psychosis, did
not moderate the treatment e!cacy of MCT+ relative to CogPack.
Limitations: Participation of both treatment groups in group MCT as a part of standard care, possibly leading to
additional e"ects on delusional severity.
Conclusions: Patients with low self-esteem and those who are prone to jumping-to-conclusions seem to parti-
cularly bene#t from MCT+. Our results can help inform clinical practice as they provide speci#c criteria for
selecting patients for whom MCT+ is most appropriate.
1. Introduction
Delusions represent core symptoms of schizophrenia spectrum and
other psychotic disorders (American Psychiatric Association, 2013).
Treatment with antipsychotic medication has been associated with
several limitations, speci#cally only medium e"ect sizes on positive
symptoms (Haddad & Correll, 2018; Leucht et al., 2017), high treat-
ment nonadherence (Garcia et al., 2016), and side e"ects (Lally &
MacCabe, 2015). These limitations have led to increased e"orts to de-
velop specialized theory-driven interventions that target delusions and
other positive symptoms, like Cognitive Behavior Therapy for psychosis
(CBTp) (Mehl, Werner, & Lincoln, 2015) and more recently social
cognition interventions (Grant, Lawrence, Preti, Wykes, & Cella, 2017).
Metacognitive Training for psychosis (MCT) represents one of these
psychological interventions (Moritz, Veckenstedt, Randjbar, Vitzthum,
& Woodward, 2011). MCT is a manualized group treatment program
that aims to reduce delusional conviction by raising patients’ awareness
for cognitive biases associated with delusions (Garety & Freeman, 2013;
Moritz, Andreou, et al., 2014; Moritz, Pfuhl, et al., 2017), such as
jumping-to-conclusions, overcon#dence in false judgments, and belief
in$exibility/incorrigibility, using entertaining exercises. These aspects
of MCT were further developed into an individualized intervention,
MCT+, which blends elements of group MCT and CBTp (Moritz,
Veckenstedt, Randjbar, & Vitzthum, 2011). Similar to group MCT,
MCT+ targets reasoning biases frequently encountered in patients with
delusional symptoms (Andreou et al., 2017). However, whereas group
https://doi.org/10.1016/j.jbtep.2020.101547
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MCT approaches the ‘metacognitive infrastructure’ of delusions with
predominantly non-delusional scenarios, MCT+ takes a step further
and applies the learning aims to individual delusional beliefs and other
core symptoms, including techniques adapted from CBT (Andreou et al.,
2017).
Several randomized controlled trials (Andreou et al., 2017; Balzan,
Mattiske, Delfabbro, Liu, & Galletly, 2019; Moritz, Andreou, et al.,
2014; Pankowski, Kowalski, & Gaweda, 2016) as well as recent meta-
analyses (Eichner & Berna, 2016; Liu, Tang, Hung, Tsai, & Lin, 2018;
Philipp et al., 2019) have suggested that MCT and MCT+ are e"ective
in the short- and long-term treatment of delusions and other positive
symptoms. However, an earlier published negative meta-analysis in-
cluding fewer studies suggested that MCT might not be suitable for all
patients (van Oosterhout et al., 2016). Similarly, negative reviews and
meta-analyses (Jauhar et al., 2014; Jauhar, Laws, & McKenna, 2019;
Jones et al., 2018) have questioned the general view of CBTp as an
e"ective treatment for all patients with psychosis. Given the recently
growing focus on individualized prediction of patient outcomes in
psychiatry, research on patient characteristics that may predict or
moderate treatment e!cacy and outcome for psychological interven-
tions is highly relevant. Treatment that is likely to fail an individual is
to be avoided for reasons of cost-e"ectiveness but also because of di-
minishing returns after each new treatment (Bücker, Schnakenberg,
Karyotaki, Moritz, & Westermann, in press).
Regarding CBTp, predictors of treatment outcome have been elu-
cidated in several studies. A recently performed systematic review re-
ported that female gender, older age, higher clinical insight at baseline,
shorter illness duration and higher educational attainment all predicted
better outcome in CBT interventions (for systematic review see
O'Kee"e, Conway, & McGuire, 2017). Inconsistent results were found
for higher baseline symptom severity, neuropsychological functioning
and cognitive $exibility (O'Kee"e et al., 2017). So far, there is only one
study that has speci#cally analyzed moderators of treatment outcome in
group MCT (Moritz, Menon, Andersen, Woodward, & Gallinat, 2018).
Results showed that low baseline self-esteem, social anxiety and a po-
sitive appraisal of the intervention were consistently associated with
improved short- and long-term outcomes in group MCT relative to an
active control intervention (Moritz et al., 2018). Additionally, short-
term delusional outcome was predicted by low quality of life, high
baseline distress, and excitement, as well as a lowered decision
threshold (only at trend-level) (Moritz et al., 2018). Neurocognitive
measures such as processing speed, selective attention, and verbal
memory did not signi#cantly moderate treatment outcome. However,
according to the authors of the study, these #ndings might not gen-
eralize to other forms of metacognitive training, such as individualized
MCT+ for psychosis (Moritz et al., 2018).
As mentioned before, the identi#cation of patients who are more
likely to bene#t from specialized interventions is of great importance.
Thus, the present study aimed to explore potential predictors of
MCT+ e!cacy on delusions and other positive symptoms. To meet this
purpose, we explored moderators of selective MCT+ e!cacy using
data from a randomized rater-blind controlled trial in patients with
psychotic disorders, in which MCT+ was compared to an active control
intervention with no expected e"ect on positive symptoms (compu-
terized cognitive training). We were particularly interested in the
moderating e"ects of reasoning style, self-esteem, quality of life and
cognitive functioning that have been reported to predict response in
group MCT and CBTp. Additionally, for the #rst time, we investigated
whether patients’ subjective appraisal of and attitudes toward their
psychotic symptoms might moderate symptomatic outcomes following
MCT+.
2. Materials and methods
2.1. Participants and setting
All data analyzed in this study were collected within the context of a
monocentric, rater-blind, randomized controlled clinical trial (Andreou
et al., 2017) carried out at the Department of Psychiatry and Psy-
chotherapy of the University Medical Center Hamburg-Eppendorf
(Germany). A more detailed description of the overall trial and its main
#ndings can be found elsewhere (Andreou et al., 2017).
A total of 92 patients with non-a"ective psychotic disorders and
current or past delusions were recruited among in- and outpatients
treated at the Psychosis Center of the Department between January
2013 and July 2015. The trial was approved by the Ethics Committee of
the German Psychology Association. All patients provided written in-
formed consent before entering the trial.
Broad inclusion criteria were applied to recruit a representative
clinical patient population: age 18–65 years, a DSM-IV diagnosis of a
schizophrenia spectrum disorder con#rmed with the Mini
Neuropsychiatric Interview (Sheehan et al., 1998), and present or prior
delusional ideas. Exclusion criteria were age<18 years, a primary
diagnosis of a substance use disorder, alcohol dependence in the last six
months, IQ < 70, severe organic brain disorders, previous experience
with group MCT or any of the experimental interventions (see below),
and any ongoing CBT-oriented psychotherapy.
Patients were randomized according to a computerized randomi-
zation plan to either one of two interventions: MCT+ or CogPack®
(Marker, 2003) (see 2.2 for details regarding the interventions).
Treatment arm allocation was performed observer-blind by a person
who was neither involved in the assessments nor intervention delivery.
All patients continued to receive their usual treatment throughout study
participation. Patients from both groups were allowed to take part in
MCT groups during study participation.
Assessments within the randomized controlled trial were carried out
at baseline, at 6 weeks (T1, corresponding to the completion of 12 in-
tervention sessions) and 6 months later (T2). The present analysis
considered only baseline data and data from the short-term follow-up
(T1).
2.2. Interventions
MCT+ (Andreou et al., 2017; Moritz, Veckenstedt, Randjbar, &
Vitzthum, 2011; Moritz, Veckenstedt, Randjbar, & Vitzthum, 2011) is a
manualized 12-session intervention including twice-weekly individual
therapy. The intervention focuses on highlighting the fallibility of
cognition in general and aims to encourage patients to re$ect on their
thinking styles in relation to their symptoms and everyday life
(Andreou et al., 2017). Therapy modules target prominent cognitive
biases such as jumping-to-conclusions, overcon#dence in false judg-
ments and belief in$exibility/incorrigibility. The approach further ad-
dresses self-esteem and coping with stigma and stress, as these topics
represent important treatment targets for patients (Moritz, Berna,
Jaeger, Westermann, & Nagel, 2017) and may interact with positive
symptoms. The MCT+ manual is freely available in several languages
via http://www.uke.de/mct_plus. More detailed information on
MCT+ can be found in Andreou et al. (2017) and Moritz, Veckenstedt,
Randjbar, and Vitzthum (2011).
CogPack (Marker, 2003) is a computerized cognitive training pro-
gram that targets cognitive dysfunctions frequently encountered in
patients with psychotic disorders. The intervention as well comprised
12 consecutive sessions, which were administered on personal com-
puters and covered a wide range of neuropsychological exercises in-
volving memory, reasoning, selective attention and psychomotor speed.
To match the two patient groups on therapeutic e"ort, CogPack was
used as the active control intervention.
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2.3. Outcome variables
The primary study aim was to assess potential moderators of
MCT+ e!cacy on delusions and other positive symptoms. Therefore,
delusion severity at T1 was de#ned as the primary outcome variable
and was assessed with the item P1 of the Positive and Negative
Syndrome Scale (PANSS) (Kay, Fiszbein, & Opler, 1987). The PANSS is
a widely used instrument considered as the gold standard assessment in
clinical trials (Suzuki, 2011). It has been shown to have good psycho-
metric properties (Kay, Opler, & Lindenmayer, 1989). Additionally, to
the PANSS P1 delusion item we used the positive symptoms factor ac-
cording to the #ve-factor model of the PANSS (positive symptoms,
negative symptoms, disorganized symptoms, excitement, depression)
proposed by Wallwork, Fortgang, Hashimoto, Weinberger, and
Dickinson (2012).
2.4. Moderator variables
A full description of all measures used in the original trial is pro-
vided elsewhere (Andreou et al., 2017). Here, only the measures re-
levant to the current study are described.
A broad range of di"erent variables was included to analyze mod-
erators of selective MCT+ e!cacy. All moderator variables were as-
sessed pre-intervention at baseline and comprised of jumping-to-con-
clusions, reasoning style/cognitive insight, quality of life, self-esteem,
cognition, and patients’ subjective positive and negative meanings re-
garding their psychotic illness. We decided not to include any symptom-
related moderator variables in the analyses, as this would complicate
the interpretation of results because of the high correlation with the
outcome variables and regression to the mean.
— The jumping-to-conclusions bias was assessed with the Fish Task
(Moritz, Van Quaquebeke, & Lincoln, 2012), a computerized version
of the Beads Task. The variables of interest were jumping-to-con-
clusions (de#ned in a dichotomous fashion as decisions based on
only one or two #sh), as well as the probability threshold at decision
(i.e., the minimum probability estimate, at which a decision was
made in favor of the respective lake; a higher probability threshold
indicates more cautious inference making).
— Reasoning style/cognitive insight was measured with the Beck
Cognitive Insight Scale (BCIS) (Beck, Baruch, Balter, Steer, &
Warman, 2004), which measures the ability to distance oneself from
one's ideas and re$ect upon their possible fallibility. The 15-item
self-report measure yields two scores corresponding to self-re$ec-
tiveness and self-certainty. It has been suggested (Beck & Warman,
2004) and con#rmed in patient studies (Riggs, Grant, Perivoliotis, &
Beck, 2012) that both self-re$ectiveness and self-certainty represent
in$exible reasoning styles that are associated with delusional be-
liefs. The internal consistency of the BCIS is adequate (Beck et al.,
2004; Riggs et al., 2012).
— The World Health Organization Quality of Life-BREF (WHOQOL-
BREF) (Murphy, Herrman, Hawthorne, Pinzone, & Evert, 2000) item
1 (overall quality of life) was used as a measure of overall life sa-
tisfaction.
— Self-esteem was assessed with the Rosenberg Self-Esteem Scale
(Collani & Herzberg, 2003), a widely used 10-item self-report
measure.
— The d2-test (Brickenkamp, 1978) measures selective attention and
was included as a cognitive moderator variable. Higher values can
be interpreted as better attentional performance.
— To investigate whether patients' subjective appraisal of and attitudes
towards their psychotic symptoms might moderate MCT+ e!cacy,
a shortened version of the Subjective Sense in Psychosis
Questionnaire (SUSE) (Klapheck, Nordmeyer, Cronjäger, Naber, &
Bock, 2012) was used. The latter measures the meaning of psychoses
within the #ve subscales biographical integration, positive
(enriching) and negative (burdening) symptom experience as well as
positive and negative consequences of psychosis on a 4-point Likert
scale. To facilitate analyses, two mean scores were calculated re-
$ecting positive and negative experiences and consequences of
psychosis. Higher values on the positive scale re$ect higher ap-
praisal of positive symptoms, while higher values on the negative
scale re$ect higher negative appraisal of positive symptoms.
2.5. Statistical analyses
All statistical analyses were conducted using the R environment for
statistical computing (R Development Core Team, 2019).
To investigate potential moderators of MCT+ e!cacy on delusions
and other positive symptoms, we applied linear mixed-e"ects models
using the lme4 package (Bates, Maechler, Bolker, & Walker, 2014) for R
(R Development Core Team, 2019). For each moderator variable, one
mixed-e"ects model was #tted that included group (MCT+ vs. Cog-
Pack), time (baseline vs. T1), and the corresponding moderator vari-
able, as well as all possible two and three-way interactions, as #xed
e"ects factors. Additionally, the models included an intercept that
randomly varied per subject. Continuous moderator variables were z-
transformed to get fully standardized regression coe!cients. Visual
inspection of the model residual plots did not reveal any obvious de-
viations from homoscedasticity or normality. The main e"ects of group
(reported in (Andreou et al., 2017)) and time were not of interest and
will thus not be reported. We were mainly interested in the results of
the three-way interactions, which allowed us to investigate speci#c
moderators of MCT+ e!cacy. In case of signi#cant three-way inter-
actions, two-way interactions between group and time were tested for
high and low values of the moderator to determine di"erences in
MCT+ and CogPack e!cacy depending on the moderator. However, in
the absence of signi#cant three-way interaction e"ects, we also report
signi#cant two-way interactions between the respective moderator and
time (baseline vs. T1) to indicate potential predictors of outcome irre-
spective of the type of treatment. Testing was two-tailed at a 5% sig-
ni#cance level. We did not apply any correction of multiple testing
because we were interested in analyzing potential treatment mod-
erators in a rather new and unexplored area of research. Thus, we re-
frained from formulating directed hypotheses and analyses are con-
sidered being of exploratory nature.
Due to signi#cant baseline di"erences in delusional severity and
both positive and negative symptoms between MCT+ and CogPack
patients, we additionally conducted all analyses on predictors of dif-
ferential treatment response with subsets of the MCT+ and CogPack




Compared to the MCT+ group, patients in the CogPack group
showed signi#cantly higher baseline delusional severity and positive
symptoms, and signi#cantly lower baseline negative symptoms. The
two intervention groups did not di"er on any of the other investigated
variables at baseline (see Table 1).
3.2. Moderation: predictors of di!erential treatment response (MCT+ vs.
CogPack)
Signi#cant three-way interactions between group, time and baseline
jumping-to-conclusions measures indicated that the improvement in
delusional severity in response to MCT+ as compared to CogPack was
dependent on both jumping-to-conclusions (decisions based on ! 2
#sh) (! = "1.71, SE = 0.53, p = 0.002) and decision threshold in the
Fish Task (! = 0.74, SE = 0.25, p = 0.003). Follow-up two-way
L. Leanza, et al. -RXUQDORI%HKDYLRU7KHUDS\DQG([SHULPHQWDO3V\FKLDWU\

analyses according to the presence or absence of jumping-to-conclu-
sions at baseline indicated that patients with the jumping-to-conclu-
sions bias at baseline showed signi#cantly larger improvements in the
PANSS delusion score over time following MCT+ than CogPack (group
x time interaction e"ect ! = "1.18, SE = 0.42, p = 0.008), while this
was not the case in patients without the jumping-to-conclusions bias at
baseline (group x time interaction e"ect ! = 0.53, SE = 0.32,
p = 0.109) (see Fig. 1). Similarly, a lowered decision threshold was
associated with trend-wise larger improvements in delusional severity
over time in the MCT+ relative to the CogPack group (group x time
interaction e"ect ! = "0.70, SE = 0.40, p = 0.088), compared to
patients with a higher decision threshold (group x time interaction
e"ect ! = 0.52, SE = 0.33, p = 0.124) (see Fig. 2).
Additionally, signi#cant three-way interactions between group,
time and baseline self-esteem revealed that the improvement of delu-
sional severity in response to MCT+ as compared to CogPack was de-
pendent on self-esteem (! = 0.62, SE = 0.26, p = 0.020). As shown in
Fig. 3, follow-up analyses indicated that low baseline self-esteem (group
x time interaction e"ect ! = "0.29, SE = 0.35, p = 0.406) tended to
be associated with a higher delusional reduction following MCT+ than
following CogPack, compared to high baseline self-esteem (group x
time interaction e"ect ! = 0.20, SE = 0.40, p = 0.615), even though
no signi#cant two-way interactions emerged.
With respect to overall positive symptoms, signi#cant three-way
Table 1
Sample description and treatment characteristics.
MCT+ CogPack
n mean SD score range n mean SD score range t/!2 p
Gender (m/f) 21/25 30/16 3.56 0.09
Age in years 36.91 12.5 18.0–63.0 35.59 13.1 19.0–67.0 0.50 0.62
Years of education 11.65 1.7 9.0–16.0 11.27 2.1 4.0–14.0 0.94 0.35
IQ 105.42 12.2 83.0–133.0 100.91 11.5 71.0–125.0 1.78 0.08
d2-Test - selective attention 153.69 50.7 17.0–292.0 147.66 39.2 38.0–223.0 "0.63 0.53
CPZ dose at T0 440.96 449.5 35.7–2375.0 420.24 349.9 50.0–1504.3 0.85 0.40
Symptoms
PANSS
P1 (delusions) 2.59 1.3 1–5 3.24 1.7 1–6 2.05 0.04
total score 49.78 13.0 30–88 49.35 12.8 31–86 0.16 0.87
positive 7.37 3.1 4–14 9.33 4.4 4–20 2.46 0.02
negative 10.83 4.8 6–25 8.30 2.9 6–20 3.06 0.003
disorganization 5.30 2.2 3–11 5.76 2.5 3–12 0.92 0.36
excitement 4.74 1.3 4–9 5.17 1.5 4–9 1.48 0.14
depression 6.85 3.1 3–14 5.74 2.7 3–14 1.83 0.07
Reasoning style
Fish Task - draws to decision 4.02 2.8 1–11 3.44 2.6 1–11 1.02 0.31
Fish Task - decision threshold 79.22 19.3 10–100 78.47 22.5 20–100 0.17 0.87
BCIS self-certainty 13.84 2.8 8–20 14.74 2.9 8–21 1.48 0.14
BCIS self-re$ectiveness 23.89 4.1 17–36 24.29 5.0 13–35 0.12 0.68
Quality of Life & self-esteem
Rosenberg self-esteem scale 16.82 8.3 0–35 19.82 8.2 "1–35 1.72 0.89
WHOQOL-BREF overall quality of life 2.93 1.0 1–5 3.16 1.0 1–5 1.06 0.29
Subjective symptom appraisal
SUSE - positive appraisal 2.54 0.78 1–4 2.65 0.67 1–4 0.71 0.48
SUSE – negative appraisal 2.40 0.56 1–4 2.26 0.61 1–4 "1.14 0.26
Note: CPZ: Chlorpromazine equivalent dosage; PANSS: Positive and Negative Syndrome Scale; BCIS: Beck Cognitive Insight Scale; WHOQOL-BREF: The World Health
Organization Quality of Life-BREF; SUSE: Subjective Sense in Psychosis Questionnaire.
Fig. 1. Moderation of treatment response:
Percentual symptom improvement in delusional
severity and overall positive symptoms across
treatment groups for patients with and without
baseline jumping-to-conclusions. Please note
that, in contrast to the statistical models de-
scribed in Methods and Results, graphs do not
include missing data.
L. Leanza, et al. -RXUQDORI%HKDYLRU7KHUDS\DQG([SHULPHQWDO3V\FKLDWU\

interactions between group, time and jumping-to-conclusions measures
were found. The improvement of overall positive symptoms in response
to MCT+ as compared to CogPack was again dependent on both
jumping-to-conclusions (! = "3.91, SE = 1.26, p = 0.003) and de-
cision threshold in the Fish Task (! = 1.46, SE = 0.61, p = 0.019). As
shown in Figs. 1 and 2, presence of baseline jumping-to-conclusions
(group x time interaction e"ect ! = "2.19, SE = 1.25, p = 0.089) and
a lowered decision threshold (group x time interaction e"ect
! = "0.02, SE = 0.99, p = 0.987) were associated with larger overall
symptom improvement following MCT+ relative to CogPack, while the
relative bene#t of MCT+ disappeared in patients with a high decision
threshold at baseline (group x time interaction e"ect ! = 0.71,
SE = 0.82, p = 0.389) and those without jumping-to-conclusions
(group x time interaction e"ect ! = 1.69, SE = 0.62, p = 0.009).
None of the other variables investigated signi#cantly moderated
treatment outcome (all p > 0.10).
The matching procedure resulted in MCT+ and CogPack groups
each consisting of 36 patients that no longer di"ered in baseline psy-
chopathology. We found that all results of the moderator analyses re-
mained the same, except for the #nding that the previously signi#cant
three-way interaction between group, time and baseline self-esteem
only reached trend-wise signi#cance (p = 0.074).
3.3. Predictors of treatment response irrespective of treatment group
A signi#cant two-way interaction revealed that lower baseline se-
lective attention signi#cantly predicted higher improvement in delu-
sional severity (! = 0.31, SE = 0.14, p = 0.036) and overall positive
symptoms (! = 0.99, SE = 0.33, p = 0.004) over time independently
of the intervention group.
Fig. 2. Moderation of treatment response:
Percentual symptom improvement in delusional
severity and overall positive symptoms across
treatment groups and levels of decision threshold
(dichotomized along the median: decision
threshold ! 80% = low; decision threshold >
80% = high). Please note that, in contrast to the
statistical models described in Methods and
Results, graphs do not include missing data.
Fig. 3. Moderation of treatment response:
Percentual symptom improvement in delusional se-
verity across treatment groups and levels of self-es-
teem (dichotomized along the median: Rosenberg
self-esteem score ! 18 = low; Rosenberg self-es-
teem score > 18 = high). Please note that, in
contrast to the statistical models described in
Methods and Results, graphs do not include missing
data.
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4. Discussion
To the best of our knowledge, this is the #rst study investigating
moderators of individualized MCT+ e!cacy on delusions and overall
positive symptoms. We found that the presence of the jumping-to-
conclusions bias at baseline signi#cantly moderated treatment e!cacy
in the MCT+ group for both outcome measures delusional severity and
overall positive symptoms. Moreover, we found that baseline self-es-
teem signi#cantly moderated delusional reduction following
MCT+ relative to CogPack. These results were unlikely due to sig-
ni#cant baseline di"erences in psychopathology as the analyses in
matched treatment groups yielded the same results, except that self-
esteem moderated treatment response only on a trend-level, which
however, might have been due to reduced power.
Speci#cally, patients who were prone to the jumping-to-conclusions
bias at baseline showed a stronger decrease of delusional symptoms and
positive symptoms over time following MCT+ than following CogPack.
Additionally, we also found that a lower decision threshold was asso-
ciated with larger improvements in delusional severity in the
MCT+ compared to the CogPack intervention. The reported e"ects are
consistent with the aim of MCT+ to improve delusions as well as po-
sitive symptoms by improving cognitive biases. The jumping-to-con-
clusions bias is also associated with neurocognitive de#cits in verbal
and working memory (Krezolek, Pionke, Banaszak, Kokoszka, &
Gaweda, 2019), and thus one might expect patients with jumping-to-
conclusions to also bene#t from the improvement of these de#cits
through the control intervention (CogPack). However, improvement in
jumping-to-conclusions resulting merely from better neurocognitive
performance does not necessarily translate into a decline in delusion
severity, as we have shown in a previous study (Andreou et al., 2015).
We suggested then (Andreou et al., 2015) that the core element of MCT,
i.e. explicit education on cognitive biases and on the importance of
adequate evidence gathering before reaching a conclusion, is the de-
cisive link between more cautious inference drawing and delusion im-
provement. Our present #ndings are consistent with this view, showing
that patients who display the greatest improvement in delusions and
positive symptoms following MCT+ are those who are prone to the
jumping-to-conclusions bias at baseline.
Low self-esteem additionally predicted better treatment response to
MCT+ relative to CogPack. This result is in line with Moritz et al.
(2018), who found that low baseline self-esteem predicted improved
outcomes in group MCT relative to CogPack. It has previously been
suggested that increased self-esteem might be associated with over-
con#dence in errors (Ho"rage, 2004), a cognitive bias found in patients
with schizophrenia, which is characterized by overcon#dence in false
inferences and judgments (for review see Balzan, 2016). Moreover,
Moritz et al. (2015) found that the latter bias was more pronounced in
patients who experienced subjective feelings of competence in a re-
spective domain of question. It may thus be speculated that low self-
esteem might be associated with reduced overcon#dence in errors and/
or feelings of competence (Moritz et al., 2015), making patients more
amenable to question their own beliefs and therefore more open to the
“seeds of doubt” that MCT+ seeks to plant. Else, MCT+ may improve
negative beliefs patients hold about themselves, which have been found
to be a potential risk factor for future delusional symptoms (Freeman &
Garety, 2014).
Selective attention did not signi#cantly moderate di"erences in
treatment outcome between MCT+ and CogPack but instead reached
statistical signi#cance irrespectively of the intervention group (two-
way interactions moderator and time). Unexpectedly, patients with
lowered baseline selective attention showed higher improvement in
delusional severity and positive symptoms over time. Our #nding could
be associated with greater margins for change in patients with lowered
selective attention compared to patients who already presented intact
selective attention at baseline. Combined with the observation of
Moritz et al. (2018) that improvement of selective attention over time
predicted overall symptomatic outcome following both group MCT and
CogPack, it seems reasonable that larger attentional gains in patients
with lower baseline selective attention were associated with better
treatment response. This e"ect is conceivably independent of speci#c
intervention e"ects, as cognitive impairments have long been identi#ed
as predictors of worse symptomatic (Andreou et al., 2013; Holthausen
et al., 2007) and functional (for review see Bowie & Harvey, 2006;
Christensen, 2007) outcomes in psychosis.
Some negative #ndings of the present analysis merit discussion.
Concerning cognitive insight (as assessed by the BCIS), our results are in
line with Moritz et al. (2018) who found that reasoning style and
cognitive insight did not moderate treatment response in group MCT
relative to cognitive remediation. This may seem counterintuitive at
#rst, given the signi#cant moderating e"ect of a cognitive bias
(jumping-to-conclusions) in the present analysis. However, it has pre-
viously been shown that objective cognitive biases such as jumping-to-
conclusions and subjective measures of cognitive insight are not cor-
related (Moritz et al., 2016). We also failed to #nd any e"ect of low
baseline quality of life on MCT+ e!cacy relative to CogPack, in con-
trast to #ndings by Moritz et al. (2018), who reported that low baseline
quality of life predicted better outcomes in the MCT group. This con-
trasting #nding may be setting-related, as group MCT is associated with
a stronger social dimension compared to the individualized interven-
tion. It is unlikely that the content of MCT+, the frequency of the in-
tervention and the number of sessions might have contributed in failing
to detect a signi#cant moderating e"ect of life quality, as the mentioned
factors are all highly comparable to group MCT. On the other hand,
setting di"erences between the two interventions might explain this
discrepancy, as group MCT is associated with a stronger social dimen-
sion compared to the individualized intervention. The delivery of MCT
in a group setting might stimulate a sense of belonging, bonding and
support and therefore be especially bene#cial for patients with low
social and global functioning, which has been found to be associated
with quality of life (Nevarez-Flores et al., 2019). Finally, an interesting
negative #nding was the observation that positive and negative sub-
jective appraisal of and attitudes towards psychosis did not moderate
treatment response. Thus, although positive subjective appraisal and
attitudes to psychotic symptoms have been reported to negatively a"ect
antipsychotic medication compliance (Moritz, Hünsche, & Lincoln,
2014), it may be that they are less important for outcome in the context
of an individualized psychological intervention. However, further stu-
dies are warranted to replicate this #nding since, to the best of our
knowledge, this is the very #rst study to analyze patient's subjective
appraisal of psychotic symptoms as a moderator of the e!cacy of a
psychological intervention. As a last remark, the negative results re-
garding cognitive insight and subjective experience of psychosis speak
for the broad applicability of MCT+, as they suggest that MCT+ e!-
cacy is dependent on neither subjective insight nor attitude towards the
illness.
Certain limitations should be considered regarding this study. First,
not controlling for multiple comparisons might have led to chance ef-
fects, as the possibility of #nding false-positive results is not controlled
for. However, our analyses were of exploratory nature and correction
for multiple testing might have led to type II errors limiting the capacity
to detect important moderators. Second, both MCT+ and CogPack
patients were allowed to take part in group MCT during the trial, as
group MCT was de#ned as a part of the standard clinical treatment.
Participation in group MCT may have had an additional e"ect on de-
lusional severity and positive symptoms, which we could not control
for; however, rates of MCT group participation did not di"er between
the two groups and thus are unlikely to have in$uenced the direction of
results. Third, we did not test other moderators that might be relevant
in the context of MCT+ e!cacy, such as the bias against dis-
con#rmatory evidence (BADE), which has been found to be associated
with delusional severity (Eisenacher & Zink, 2017; McLean, Mattiske, &
Balzan, 2017). Other biases, such as the BADE should be further
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examined in future studies on the e!cacy of MCT+.
In summary, individualized MCT+ seems to be more e"ective for
improving delusions and positive symptoms in patients who are prone
to jumping-to-conclusions and who have low self-esteem. Subjective
reasoning style and insight, as well as subjective attitudes towards
psychosis, do not seem to moderate the treatment e!cacy of
MCT+ relative to cognitive remediation, indicating that also patients
with low metacognitive awareness and/or particularly positive or ne-
gative attitudes towards their psychosis might still bene#t from the
intervention. Our results can inform clinical practice as they provide
speci#c criteria for selecting patients for whom MCT+ is most appro-
priate.
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